{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:23Z","timestamp":1786982183661,"version":"build-2736575974"},"reference-count":260,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12015-026-11057-0","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T02:02:19Z","timestamp":1769997739000},"page":"1067-1097","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["From Signaling Pathways to Combination Therapy: Bioactive Compounds against Cancer Stem Cells"],"prefix":"10.1007","volume":"22","author":[{"given":"P. S. V. V.","family":"Charan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikitha S.","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivruthi A.","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandana","family":"Thuyyath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adithya","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahiti","family":"Danthuluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shravani Shriya","family":"Palanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishtha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousalya","family":"Lavudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"1 Suppl 1","key":"11057_CR1","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/MD.0000000000004766","volume":"95","author":"JC Chang","year":"2016","unstructured":"Chang, J. C. (2016). Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance. Medicine, 95(1 Suppl 1), S20\u2013S25. https:\/\/doi.org\/10.1097\/MD.0000000000004766","journal-title":"Medicine"},{"issue":"1","key":"11057_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02360-2","volume":"10","author":"H Lee","year":"2025","unstructured":"Lee, H., Kim, B., Park, J., Park, S., Yoo, G., Yum, S., Kang, W., Lee, J. M., Youn, H., & Youn, B. (2025). Cancer stem cells: Landscape, challenges and emerging therapeutic innovations. Signal Transduction and Targeted Therapy, 10(1), Article 248. https:\/\/doi.org\/10.1038\/s41392-025-02360-2","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"3\u20134","key":"11057_CR3","first-page":"85","volume":"79","author":"X Ma","year":"2006","unstructured":"Ma, X., & Yu, H. (2006). Global burden of cancer. The Yale Journal of Biology and Medicine, 79(3\u20134), 85\u201394.","journal-title":"The Yale Journal of Biology and Medicine"},{"key":"11057_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.biopha.2018.07.167","volume":"107","author":"S Pravin","year":"2018","unstructured":"Pravin, S., & Sudhir, A. (2018). Integration of 3D printing with dosage forms: A new perspective for modern healthcare. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 107, 146\u2013154. https:\/\/doi.org\/10.1016\/j.biopha.2018.07.167","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"key":"11057_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9653244","volume":"2022","author":"S Bisht","year":"2022","unstructured":"Bisht, S., Nigam, M., Kunjwal, S. S., Sergey, P., Mishra, A. P., & Sharifi-Rad, J. (2022). Cancer stem cells: From an insight into the basics to recent advances and therapeutic targeting. Stem Cells International, 2022, Article 9653244. https:\/\/doi.org\/10.1155\/2022\/9653244","journal-title":"Stem Cells International"},{"issue":"4","key":"11057_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.176","volume":"3","author":"W Manni","year":"2022","unstructured":"Manni, W., & Min, W. (2022). Signaling pathways in the regulation of cancer stem cells and associated targeted therapy. MedComm (London), 3(4), Article e176. https:\/\/doi.org\/10.1002\/mco2.176","journal-title":"MedComm (London)"},{"issue":"5","key":"11057_CR7","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"issue":"2","key":"11057_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00280-020-04222-w","volume":"87","author":"U Mehraj","year":"2021","unstructured":"Mehraj, U., Dar, A. H., Wani, N. A., & Mir, M. A. (2021). Tumor microenvironment promotes breast cancer chemoresistance. Cancer Chemotherapy and Pharmacology, 87(2), 147\u2013158. https:\/\/doi.org\/10.1007\/s00280-020-04222-w","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"11057_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.semcdb.2016.09.003","volume":"64","author":"M Qian","year":"2017","unstructured":"Qian, M., Wang, D. C., Chen, H., & Cheng, Y. (2017). Detection of single cell heterogeneity in cancer. Seminars in Cell & Developmental Biology, 64, 143\u2013149. https:\/\/doi.org\/10.1016\/j.semcdb.2016.09.003","journal-title":"Seminars in Cell & Developmental Biology"},{"issue":"7","key":"11057_CR10","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3390\/cells14070538","volume":"14","author":"L Haddadin","year":"2025","unstructured":"Haddadin, L., & Sun, X. (2025). Stem cells in cancer: From mechanisms to therapeutic strategies. Cells, 14(7), 538. https:\/\/doi.org\/10.3390\/cells14070538","journal-title":"Cells"},{"key":"11057_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-7401-6_1","volume":"1692","author":"D Bakhshinyan","year":"2018","unstructured":"Bakhshinyan, D., Adile, A. A., Qazi, M. A., Singh, M., Kameda-Smith, M. M., Yelle, N., Chokshi, C., Venugopal, C., & Singh, S. K. (2018). Introduction to Cancer Stem Cells: Past, present, and future. Methods in Molecular Biology (Clifton, N.J.), 1692, 1\u201316. https:\/\/doi.org\/10.1007\/978-1-4939-7401-6_1","journal-title":"Methods in Molecular Biology (Clifton, N.J.)"},{"issue":"6","key":"11057_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.5483\/bmbrep.2017.50.6.039","volume":"50","author":"WT Kim","year":"2017","unstructured":"Kim, W. T., & Ryu, C. J. (2017). Cancer stem cell surface markers on normal stem cells. BMB Reports, 50(6), 285\u2013298. https:\/\/doi.org\/10.5483\/bmbrep.2017.50.6.039","journal-title":"BMB Reports"},{"key":"11057_CR13","doi-asserted-by":"publisher","first-page":"Unit","DOI":"10.1002\/0471141755.ph1425s61","volume":"14","author":"B Bao","year":"2013","unstructured":"Bao, B., Ahmad, A., Azmi, A. S., Ali, S., & Sarkar, F. H. (2013). Overview of cancer stem cells (CSCs) and mechanisms of their regulation: Implications for cancer therapy. Current Protocols in Pharmacology, 14, Unit-14.25. https:\/\/doi.org\/10.1002\/0471141755.ph1425s61","journal-title":"Current Protocols in Pharmacology"},{"key":"11057_CR14","doi-asserted-by":"crossref","unstructured":"Zu, F., Chen, C., Geng, Q., Li, H., Chan, B., Luo, G., ... & Sheng, W. (2025). Smad2 cooperating with TGIF2 contributes to EMT and cancer stem cells properties in pancreatic cancer via Co targeting SOX2. International Journal of Biological Sciences, 21(2), 524.","DOI":"10.7150\/ijbs.102381"},{"issue":"19","key":"11057_CR15","doi-asserted-by":"publisher","first-page":"8721","DOI":"10.7150\/thno.41648","volume":"10","author":"T Huang","year":"2020","unstructured":"Huang, T., Song, X., Xu, D., Tiek, D., Goenka, A., Wu, B., Sastry, N., Hu, B., & Cheng, S. Y. (2020). Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics, 10(19), 8721\u20138743. https:\/\/doi.org\/10.7150\/thno.41648","journal-title":"Theranostics"},{"issue":"21","key":"11057_CR16","doi-asserted-by":"publisher","first-page":"9891","DOI":"10.1111\/jcmm.16939","volume":"25","author":"X Cui","year":"2021","unstructured":"Cui, X., Liu, R., Duan, L., Cao, D., Zhang, Q., & Zhang, A. (2021). CAR-T therapy: Prospects in targeting cancer stem cells. Journal of Cellular and Molecular Medicine, 25(21), 9891\u20139904. https:\/\/doi.org\/10.1111\/jcmm.16939","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"8","key":"11057_CR17","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s12015-024-10786-4","volume":"20","author":"LE Rabie","year":"2024","unstructured":"Rabie, L. E., Mohran, A. A., Gaber, K. A., Ali, N. M., Abd El Naby, A. M., Ghoniem, E. A., Abd Elmaksod, B. A., & Abdallah, A. N. (2024). Beyond conventional treatments: Exploring CAR-T cell therapy for cancer stem cell eradication. Stem Cell Reviews and Reports, 20(8), 2001\u20132015. https:\/\/doi.org\/10.1007\/s12015-024-10786-4","journal-title":"Stem Cell Reviews and Reports"},{"issue":"7","key":"11057_CR18","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.apsb.2020.12.015","volume":"11","author":"J Masoumi","year":"2021","unstructured":"Masoumi, J., Jafarzadeh, A., Abdolalizadeh, J., Khan, H., Philippe, J., Mirzaei, H., & Mirzaei, H. R. (2021). Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects. Acta Pharmaceutica Sinica. B, 11(7), 1721\u20131739. https:\/\/doi.org\/10.1016\/j.apsb.2020.12.015","journal-title":"Acta Pharmaceutica Sinica. B"},{"issue":"12","key":"11057_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/biom9120758","volume":"9","author":"S Subramaniam","year":"2019","unstructured":"Subramaniam, S., Selvaduray, K. R., & Radhakrishnan, A. K. (2019). Bioactive compounds: Natural defense against cancer? Biomolecules, 9(12), Article 758. https:\/\/doi.org\/10.3390\/biom9120758","journal-title":"Biomolecules"},{"key":"11057_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01280","volume":"11","author":"L Walcher","year":"2020","unstructured":"Walcher, L., Kistenmacher, A. K., Suo, H., Kitte, R., Dluczek, S., Strau\u00df, A., Blaudszun, A. R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020). Cancer stem cells-origins and biomarkers: Perspectives for targeted personalized therapies. Frontiers in Immunology, 11, Article 1280. https:\/\/doi.org\/10.3389\/fimmu.2020.01280","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"11057_CR21","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nm.4409","volume":"23","author":"E Batlle","year":"2017","unstructured":"Batlle, E., & Clevers, H. (2017). Cancer stem cells revisited. Nature Medicine, 23(10), 1124\u20131134. https:\/\/doi.org\/10.1038\/nm.4409","journal-title":"Nature Medicine"},{"issue":"1","key":"11057_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-00627-5","volume":"19","author":"Y Li","year":"2021","unstructured":"Li, Y., Wang, Z., Ajani, J. A., & Song, S. (2021). Drug resistance and cancer stem cells. Cell Communication and Signaling, 19(1), Article 19. https:\/\/doi.org\/10.1186\/s12964-020-00627-5","journal-title":"Cell Communication and Signaling"},{"issue":"7","key":"11057_CR23","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s12015-022-10426-9","volume":"18","author":"A Nayak","year":"2022","unstructured":"Nayak, A., Warrier, N. M., & Kumar, P. (2022). Cancer stem cells and the tumor microenvironment: Targeting the critical crosstalk through nanocarrier systems. Stem Cell Reviews and Reports, 18(7), 2209\u20132233. https:\/\/doi.org\/10.1007\/s12015-022-10426-9","journal-title":"Stem Cell Reviews and Reports"},{"issue":"18","key":"11057_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cells11182828","volume":"11","author":"X Rao","year":"2022","unstructured":"Rao, X., Zhang, C., Luo, H., Zhang, J., Zhuang, Z., Liang, Z., & Wu, X. (2022). Targeting gastric cancer stem cells to enhance treatment response. Cells, 11(18), Article 2828. https:\/\/doi.org\/10.3390\/cells11182828","journal-title":"Cells"},{"issue":"2","key":"11057_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrclinonc.2010.196","volume":"8","author":"N Takebe","year":"2011","unstructured":"Takebe, N., Harris, P. J., Warren, R. Q., & Ivy, S. P. (2011). Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nature Reviews. Clinical Oncology, 8(2), 97\u2013106. https:\/\/doi.org\/10.1038\/nrclinonc.2010.196","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"11","key":"11057_CR26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI159839","volume":"132","author":"EE Wicks","year":"2022","unstructured":"Wicks, E. E., & Semenza, G. L. (2022). Hypoxia-inducible factors: Cancer progression and clinical translation. Journal of Clinical Investigation, 132(11), Article e159839. https:\/\/doi.org\/10.1172\/JCI159839","journal-title":"Journal of Clinical Investigation"},{"key":"11057_CR27","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9918379","volume":"2021","author":"I Chattopadhyay","year":"2021","unstructured":"Chattopadhyay, I., Ambati, R., & Gundamaraju, R. (2021). Exploring the crosstalk between inflammation and epithelial-mesenchymal transition in cancer. Mediators of Inflammation, 2021, Article 9918379. https:\/\/doi.org\/10.1155\/2021\/9918379","journal-title":"Mediators of Inflammation"},{"issue":"16","key":"11057_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14163906","volume":"14","author":"RA Glabman","year":"2022","unstructured":"Glabman, R. A., Choyke, P. L., & Sato, N. (2022). Cancer-associated fibroblasts: Tumorigenicity and targeting for cancer therapy. Cancers, 14(16), Article 3906. https:\/\/doi.org\/10.3390\/cancers14163906","journal-title":"Cancers"},{"issue":"3","key":"11057_CR29","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E., & Joyce, J. A. (2023). The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell, 41(3), 374\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016","journal-title":"Cancer Cell"},{"issue":"1","key":"11057_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01322-3","volume":"15","author":"Y Yan","year":"2022","unstructured":"Yan, Y., Huang, L., Liu, Y., Yi, M., Chu, Q., Jiao, D., & Wu, K. (2022). Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: Implications for antitumor immunity. Journal of Hematology & Oncology, 15(1), Article 104. https:\/\/doi.org\/10.1186\/s13045-022-01322-3","journal-title":"Journal of Hematology & Oncology"},{"key":"11057_CR31","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.matbio.2015.01.022","volume":"44","author":"K Kessenbrock","year":"2015","unstructured":"Kessenbrock, K., Wang, C. Y., & Werb, Z. (2015). Matrix metalloproteinases in stem cell regulation and cancer. Matrix Biology\u202f: Journal of the International Society for Matrix Biology, 44, 184\u2013190. https:\/\/doi.org\/10.1016\/j.matbio.2015.01.022","journal-title":"Matrix Biology : Journal of the International Society for Matrix Biology"},{"issue":"2","key":"11057_CR32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10549-012-2075-8","volume":"134","author":"BG Debeb","year":"2012","unstructured":"Debeb, B. G., Cohen, E. N., Boley, K., Freiter, E. M., Li, L., Robertson, F. M., Reuben, J. M., Cristofanilli, M., Buchholz, T. A., & Woodward, W. A. (2012). Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Research and Treatment, 134(2), 495\u2013510. https:\/\/doi.org\/10.1007\/s10549-012-2075-8","journal-title":"Breast Cancer Research and Treatment"},{"key":"11057_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jconrel.2018.09.025","volume":"290","author":"PPG Guimaraes","year":"2018","unstructured":"Guimaraes, P. P. G., Tan, M., Tammela, T., Wu, K., Chung, A., Oberli, M., Wang, K., Spektor, R., Riley, R. S., Viana, C. T. R., Jacks, T., Langer, R., & Mitchell, M. J. (2018). Potent in vivo lung cancer Wnt signaling inhibition via cyclodextrin-LGK974 inclusion complexes. Journal of Controlled Release, 290, 75\u201387. https:\/\/doi.org\/10.1016\/j.jconrel.2018.09.025","journal-title":"Journal of Controlled Release"},{"issue":"12","key":"11057_CR34","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.bcp.2011.07.093","volume":"82","author":"BN Singh","year":"2011","unstructured":"Singh, B. N., Shankar, S., & Srivastava, R. K. (2011). Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications. Biochemical Pharmacology, 82(12), 1807\u20131821. https:\/\/doi.org\/10.1016\/j.bcp.2011.07.093","journal-title":"Biochemical Pharmacology"},{"issue":"1","key":"11057_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ph17010127","volume":"17","author":"YC Chung","year":"2024","unstructured":"Chung, Y. C., Chen, S. J., Huang, C. C., Liu, W. C., Lai, M. T., Kao, T. Y., Yang, W. S., Yang, C. H., Hsu, C. P., & Chang, J. F. (2024). Tocilizumab exerts anti-tumor effects on colorectal carcinoma cell xenografts corresponding to expression levels of Interleukin-6 receptor. Pharmaceuticals (Basel), 17(1), Article 127. https:\/\/doi.org\/10.3390\/ph17010127","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"11057_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s13205-023-03742-5","volume":"13","author":"X Qin","year":"2023","unstructured":"Qin, X., Ruan, H., Yuan, L., & Lin, L. (2023). Colorectal cancer tumor stem cells mediate bevacizumab resistance through the signal IL-22-STAT3 signaling pathway. 3 Biotech, 13(10), Article 327. https:\/\/doi.org\/10.1007\/s13205-023-03742-5","journal-title":"3 Biotech"},{"issue":"5","key":"11057_CR37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2174\/1566524018666171205113959","volume":"17","author":"Y Xu","year":"2017","unstructured":"Xu, Y., Zhou, X., Mei, M., & Ren, Y. (2017). Reprograming carcinoma associated fibroblasts by microRNAs. Current Molecular Medicine, 17(5), 341\u2013349. https:\/\/doi.org\/10.2174\/1566524018666171205113959","journal-title":"Current Molecular Medicine"},{"key":"11057_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113906","volume":"156","author":"E Rouzbahani","year":"2022","unstructured":"Rouzbahani, E., Majidpoor, J., Najafi, S., & Mortezaee, K. (2022). Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 156, Article 113906. https:\/\/doi.org\/10.1016\/j.biopha.2022.113906","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"issue":"11","key":"11057_CR39","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.3390\/cells10113135","volume":"10","author":"S Gampala","year":"2021","unstructured":"Gampala, S., & Yang, J.-Y. (2021). Hedgehog pathway inhibitors against tumor microenvironment. Cells, 10(11), 3135. https:\/\/doi.org\/10.3390\/cells10113135","journal-title":"Cells"},{"issue":"1","key":"11057_CR40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10637-014-0166-6","volume":"33","author":"NK LoConte","year":"2015","unstructured":"LoConte, N. K., Razak, A. R., Ivy, P., Tevaarwerk, A., Leverence, R., Kolesar, J., Siu, L., Lubner, S. J., Mulkerin, D. L., Schelman, W. R., Deming, D. A., Holen, K. D., Carmichael, L., Eickhoff, J., & Liu, G. (2015). A multicenter phase 1 study of \u03b3 -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Investigational New Drugs, 33(1), 169\u2013176. https:\/\/doi.org\/10.1007\/s10637-014-0166-6","journal-title":"Investigational New Drugs"},{"issue":"11","key":"11057_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027306","volume":"6","author":"BN Singh","year":"2011","unstructured":"Singh, B. N., Fu, J., Srivastava, R. K., & Shankar, S. (2011). Hedgehog signaling antagonist GDC-0449 (vismodegib) inhibits pancreatic cancer stem cell characteristics: Molecular mechanisms. PLoS ONE, 6(11), Article e27306. https:\/\/doi.org\/10.1371\/journal.pone.0027306","journal-title":"PLoS ONE"},{"issue":"6","key":"11057_CR42","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1365-2184.2012.00849.x","volume":"45","author":"Z Liu","year":"2012","unstructured":"Liu, Z., Ouyang, L., Peng, H., & Zhang, W. Z. (2012). Oridonin: Targeting programmed cell death pathways as an anti-tumour agent. Cell Proliferation, 45(6), 499\u2013507. https:\/\/doi.org\/10.1111\/j.1365-2184.2012.00849.x","journal-title":"Cell Proliferation"},{"issue":"10","key":"11057_CR43","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqaa152","volume":"161","author":"E Smart","year":"2020","unstructured":"Smart, E., Semina, S. E., & Frasor, J. (2020). Update on the role of NF\u03baB in promoting aggressive phenotypes of estrogen receptor-positive breast cancer. Endocrinology, 161(10), Article bqaa152. https:\/\/doi.org\/10.1210\/endocr\/bqaa152","journal-title":"Endocrinology"},{"issue":"13","key":"11057_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28135082","volume":"28","author":"J Cai","year":"2023","unstructured":"Cai, J., Hu, Q., He, Z., Chen, X., Wang, J., Yin, X., Ma, X., & Zeng, J. (2023). Scutellaria baicalensis Georgi and their natural flavonoid compounds in the treatment of ovarian cancer: A review. Molecules, 28(13), Article 5082. https:\/\/doi.org\/10.3390\/molecules28135082","journal-title":"Molecules"},{"key":"11057_CR45","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.2147\/DDDT.S251614","volume":"14","author":"R Wang","year":"2020","unstructured":"Wang, R., Lu, X., & Yu, R. (2020). Lycopene inhibits epithelial-mesenchymal transition and promotes apoptosis in oral cancer via PI3K\/AKT\/m-TOR signal pathway. Drug Design, Development and Therapy, 14, 2461\u20132471. https:\/\/doi.org\/10.2147\/DDDT.S251614","journal-title":"Drug Design, Development and Therapy"},{"key":"11057_CR46","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2147\/CMAR.S242329","volume":"12","author":"Y Wang","year":"2020","unstructured":"Wang, Y., Liu, Y., Du, X., Ma, H., & Yao, J. (2020). The anti-cancer mechanisms of berberine: A review. Cancer Management and Research, 12, 695\u2013702. https:\/\/doi.org\/10.2147\/CMAR.S242329","journal-title":"Cancer Management and Research"},{"key":"11057_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00203","author":"V Snyder","year":"2018","unstructured":"Snyder, V., Reed-Newman, T. C., Arnold, L., Thomas, S. M., & Anant, S. (2018). Cancer stem cell metabolism and potential therapeutic targets. Frontiers in Oncology. https:\/\/doi.org\/10.3389\/fonc.2018.00203","journal-title":"Frontiers in Oncology"},{"issue":"3","key":"11057_CR48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti, M. V., & Locasale, J. W. (2016). The warburg effect: How does it benefit cancer cells? Trends in Biochemical Sciences, 41(3), 211\u2013218. https:\/\/doi.org\/10.1016\/j.tibs.2015.12.001","journal-title":"Trends in Biochemical Sciences"},{"issue":"7","key":"11057_CR49","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1080\/09553002.2019.1589653","volume":"95","author":"P Vaupel","year":"2019","unstructured":"Vaupel, P., Schmidberger, H., & Mayer, A. (2019). The warburg effect: Essential part of metabolic reprogramming and central contributor to cancer progression. International Journal of Radiation Biology, 95(7), 912\u2013919. https:\/\/doi.org\/10.1080\/09553002.2019.1589653","journal-title":"International Journal of Radiation Biology"},{"issue":"12","key":"11057_CR50","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/bjc.2016.152","volume":"114","author":"P Sancho","year":"2016","unstructured":"Sancho, P., Barneda, D., & Heeschen, C. (2016). Hallmarks of cancer stem cell metabolism. British Journal of Cancer, 114(12), 1305\u20131312. https:\/\/doi.org\/10.1038\/bjc.2016.152","journal-title":"British Journal of Cancer"},{"key":"11057_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1587-0","author":"S Sun","year":"2019","unstructured":"Sun, S., Xue, D., Chen, Z., Ou-Yang, Y., Zhang, J., Mai, J., Gu, J., Lu, W., Liu, X., Liu, W., Sheng, L., Lu, B., Lin, Y., Xing, F., Chen, Z., Mou, Y., Yan, G., Zhu, W., & Sai, K. (2019). R406 elicits anti-Warburg effect via Syk-dependent and-independent mechanisms to trigger apoptosis in glioma stem cells. Cell Death and Disease. https:\/\/doi.org\/10.1038\/s41419-019-1587-0","journal-title":"Cell Death and Disease"},{"issue":"20","key":"11057_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25204831","volume":"25","author":"J Li","year":"2020","unstructured":"Li, J., Eu, J. Q., Kong, L. R., Wang, L., Lim, Y. C., Goh, B. C., & Wong, A. L. A. (2020). Targeting metabolism in cancer cells and the tumour microenvironment for cancer therapy. Molecules, 25(20), Article 4831. https:\/\/doi.org\/10.3390\/molecules25204831","journal-title":"Molecules"},{"key":"11057_CR53","doi-asserted-by":"crossref","unstructured":"Khan, W., Augustine, D., Rao, R. S., Patil, S., Awan, K. H., Sowmya, S. V., ... & Prasad, K. (2021). Lipid metabolism in cancer: A systematic review. Journal of Carcinogenesis, 20, 4.","DOI":"10.4103\/jcar.JCar_15_20"},{"issue":"1","key":"11057_CR54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1021\/cbmi.4c00050","volume":"3","author":"GA Gonzalez","year":"2024","unstructured":"Gonzalez, G. A., Osuji, E. U., Fiur, N. C., Clark, M. G., Ma, S., Lukov, L. L., & Zhang, C. (2024). Alteration of lipid metabolism in hypoxic cancer cells. Chemical & Biomedical Imaging, 3(1), 25\u201334. https:\/\/doi.org\/10.1021\/cbmi.4c00050","journal-title":"Chemical & Biomedical Imaging"},{"key":"11057_CR55","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/s41416-019-0451-4","volume":"120","author":"R Munir","year":"2019","unstructured":"Munir, R., Lisec, J., Swinnen, J. V., et al. (2019). Lipid metabolism in cancer cells under metabolic stress. British Journal of Cancer, 120, 1090\u20131098. https:\/\/doi.org\/10.1038\/s41416-019-0451-4","journal-title":"British Journal of Cancer"},{"issue":"1","key":"11057_CR56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mco2.27","volume":"2","author":"Y Fu","year":"2020","unstructured":"Fu, Y., Zou, T., Shen, X., Nelson, P. J., Li, J., Wu, C., Yang, J., Zheng, Y., Bruns, C., Zhao, Y., Qin, L., & Dong, Q. (2020). Lipid metabolism in cancer progression and therapeutic strategies. MedComm (London), 2(1), 27\u201359. https:\/\/doi.org\/10.1002\/mco2.27","journal-title":"MedComm (London)"},{"key":"11057_CR57","doi-asserted-by":"publisher","unstructured":"Fu, Z., Cao, X., Liu, L., Cao, X., Cui, Y., Li, X. ... Cao, J. (2020). Genistein inhibits lung cancer cell stem\u2011like characteristics by modulating MnSOD and FoxM1 expression Retraction in\/10.3892\/ol.2025.15097. Oncology Letters, 20, 2506\u20132515. https:\/\/doi.org\/10.3892\/ol.2020.11802","DOI":"10.3892\/ol.2020.11802"},{"issue":"16","key":"11057_CR58","doi-asserted-by":"publisher","first-page":"7053","DOI":"10.7150\/thno.41388","volume":"10","author":"H Li","year":"2020","unstructured":"Li, H., Feng, Z., & He, M. (2020). Lipid metabolism alteration contributes to and maintains the properties of cancer stem cells. Theranostics, 10(16), 7053\u20137069. https:\/\/doi.org\/10.7150\/thno.41388","journal-title":"Theranostics"},{"issue":"4","key":"11057_CR59","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2022.13239","volume":"23","author":"H Liu","year":"2022","unstructured":"Liu, H., Zhang, Z., Song, L., Gao, J., & Liu, Y. (2022). Lipid metabolism of cancer stem cells. Oncology Letters, 23(4), Article 119. https:\/\/doi.org\/10.3892\/ol.2022.13239","journal-title":"Oncology Letters"},{"issue":"1","key":"11057_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu, J., Xiao, Q., Xiao, J., Niu, C., Li, Y., Zhang, X., Zhou, Z., Shu, G., & Yin, G. (2022). Wnt\/\u03b2-catenin signalling: Function, biological mechanisms, and therapeutic opportunities. Signal Transduction and Targeted Therapy, 7(1), Article 3. https:\/\/doi.org\/10.1038\/s41392-021-00762-6","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"11057_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1367981","volume":"15","author":"J Du","year":"2024","unstructured":"Du, J., & Qin, H. (2024). Lipid metabolism dynamics in cancer stem cells: Potential targets for cancers. Frontiers in Pharmacology, 15, Article 1367981. https:\/\/doi.org\/10.3389\/fphar.2024.1367981","journal-title":"Frontiers in Pharmacology"},{"key":"11057_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1155774","volume":"13","author":"P Darvin","year":"2023","unstructured":"Darvin, P., & Nair, V. S. (2023). Editorial: Understanding mitochondrial dynamics and metabolic plasticity in cancer stem cells: Recent advances in cancer treatment and potential therapeutic approaches. Frontiers in Oncology, 13, Article 1155774. https:\/\/doi.org\/10.3389\/fonc.2023.1155774","journal-title":"Frontiers in Oncology"},{"issue":"15","key":"11057_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/cells11152401","volume":"11","author":"E Panieri","year":"2022","unstructured":"Panieri, E., Pinho, S. A., Afonso, G. J. M., Oliveira, P. J., Cunha-Oliveira, T., & Saso, L. (2022). NRF2 and mitochondrial function in cancer and cancer stem cells. Cells, 11(15), Article 2401. https:\/\/doi.org\/10.3390\/cells11152401","journal-title":"Cells"},{"key":"11057_CR64","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/SCCAA.S417842","volume":"16","author":"SV Garimella","year":"2023","unstructured":"Garimella, S. V., Gampa, S. C., & Chaturvedi, P. (2023). Mitochondria in cancer stem cells: From an innocent bystander to a central player in therapy resistance. Stem Cells and Cloning: Advances and Applications, 16, 19\u201341. https:\/\/doi.org\/10.2147\/SCCAA.S417842","journal-title":"Stem Cells and Cloning: Advances and Applications"},{"issue":"7","key":"11057_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/cells9071693","volume":"9","author":"JM Garc\u00eda-Heredia","year":"2020","unstructured":"Garc\u00eda-Heredia, J. M., & Carnero, A. (2020). Role of mitochondria in cancer stem cell resistance. Cells, 9(7), Article 1693. https:\/\/doi.org\/10.3390\/cells9071693","journal-title":"Cells"},{"issue":"1","key":"11057_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03558-0","volume":"24","author":"BA Mengistu","year":"2024","unstructured":"Mengistu, B. A., Tsegaw, T., Demessie, Y., Getnet, K., Bitew, A. B., Kinde, M. Z., Beirhun, A. M., Mebratu, A. S., Mekasha, Y. T., Feleke, M. G., & Fenta, M. D. (2024). Comprehensive review of drug resistance in mammalian cancer stem cells: Implications for cancer therapy. Cancer Cell International, 24(1), Article 406. https:\/\/doi.org\/10.1186\/s12935-024-03558-0","journal-title":"Cancer Cell International"},{"issue":"4","key":"11057_CR67","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1177\/0300060514527060","volume":"42","author":"T Yao","year":"2014","unstructured":"Yao, T., Wu, Z., Liu, Y., Rao, Q., & Lin, Z. (2014). Aldehyde dehydrogenase 1 (ALDH1) positivity correlates with poor prognosis in cervical cancer. The Journal of International Medical Research, 42(4), 1038\u20131042. https:\/\/doi.org\/10.1177\/0300060514527060","journal-title":"The Journal of International Medical Research"},{"issue":"1","key":"11057_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01315-w","volume":"21","author":"Y Yang","year":"2023","unstructured":"Yang, Y., Zhu, G., Yang, L., & Yang, Y. (2023). Targeting CD24 as a novel immunotherapy for solid cancers. Cell Communication and Signaling, 21(1), Article 312. https:\/\/doi.org\/10.1186\/s12964-023-01315-w","journal-title":"Cell Communication and Signaling"},{"issue":"2","key":"11057_CR69","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/s1097-2765(00)80307-x","volume":"3","author":"MG Vander Heiden","year":"1999","unstructured":"Vander Heiden, M. G., Chandel, N. S., Schumacker, P. T., & Thompson, C. B. (1999). Bcl-xL prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP\/ADP exchange. Molecular Cell, 3(2), 159\u2013167. https:\/\/doi.org\/10.1016\/s1097-2765(00)80307-x","journal-title":"Molecular Cell"},{"key":"11057_CR70","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre, A., & Weinberg, R. A. (2019). New insights into the mechanisms of epithelial\u2013mesenchymal transition and implications for cancer. Nature Reviews Molecular Cell Biology, 20, 69\u201384. https:\/\/doi.org\/10.1038\/s41580-018-0080-4","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"10","key":"11057_CR71","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s00432-014-1840-y","volume":"141","author":"D Nantajit","year":"2015","unstructured":"Nantajit, D., Lin, D., & Li, J. J. (2015). The network of epithelial-mesenchymal transition: Potential new targets for tumor resistance. Journal of Cancer Research and Clinical Oncology, 141(10), 1697\u20131713. https:\/\/doi.org\/10.1007\/s00432-014-1840-y","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"1","key":"11057_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02593-8","volume":"11","author":"F Nie","year":"2025","unstructured":"Nie, F., Sun, X., Sun, J., Zhang, J., & Wang, Y. (2025). Epithelial-mesenchymal transition in colorectal cancer metastasis and progression: Molecular mechanisms and therapeutic strategies. Cell Death Discovery, 11(1), Article 336. https:\/\/doi.org\/10.1038\/s41420-025-02593-8","journal-title":"Cell Death Discovery"},{"issue":"7","key":"11057_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3003301","volume":"23","author":"SR Rosenbaum","year":"2025","unstructured":"Rosenbaum, S. R., Fields, K. M., & Ford, H. L. (2025). Masters of adaptation: How cancer and immune cell plasticity mediates tumor progression. PLoS Biology, 23(7), Article e3003301. https:\/\/doi.org\/10.1371\/journal.pbio.3003301","journal-title":"PLoS Biology"},{"key":"11057_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.567116","volume":"10","author":"G Herbein","year":"2020","unstructured":"Herbein, G., & Nehme, Z. (2020). Polyploid giant cancer cells, a hallmark of oncoviruses and a new therapeutic challenge. Frontiers in Oncology, 10, Article 567116. https:\/\/doi.org\/10.3389\/fonc.2020.567116","journal-title":"Frontiers in Oncology"},{"key":"11057_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1611920","volume":"15","author":"P Huang","year":"2025","unstructured":"Huang, P., Wu, R., Yang, Z., Li, Y., Fei, F., & Yu, Y. (2025). Polyploid giant cancer cells and tumor budding: Translation from basic research to clinical application. Frontiers in Oncology, 15, Article 1611920. https:\/\/doi.org\/10.3389\/fonc.2025.1611920","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"11057_CR76","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/clinchem\/hvad197","volume":"70","author":"P den Hollander","year":"2024","unstructured":"den Hollander, P., Maddela, J. J., & Mani, S. A. (2024). Spatial and temporal relationship between epithelial-mesenchymal transition (EMT) and stem cells in cancer. Clinical Chemistry, 70(1), 190\u2013205. https:\/\/doi.org\/10.1093\/clinchem\/hvad197","journal-title":"Clinical Chemistry"},{"issue":"1","key":"11057_CR77","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3390\/cancers30100716","volume":"3","author":"D Kong","year":"2011","unstructured":"Kong, D., Li, Y., Wang, Z., & Sarkar, F. H. (2011). Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: Are they cousins or twins? Cancers, 3(1), 716\u2013729. https:\/\/doi.org\/10.3390\/cancers30100716","journal-title":"Cancers"},{"key":"11057_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1595362","volume":"13","author":"J Zhang","year":"2025","unstructured":"Zhang, J., Wu, H., Ren, X., Chen, Z., Ye, S., Chen, S., Fang, J., Wu, Q., & Zhao, T. (2025). Hippo\/YAP signaling\u2019s multifaceted crosstalk in cancer. Frontiers in Cell and Developmental Biology, 13, Article 1595362. https:\/\/doi.org\/10.3389\/fcell.2025.1595362","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"11057_CR79","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pbiomolbio.2025.04.001","volume":"196","author":"J Zhang","year":"2025","unstructured":"Zhang, J., Yin, R., Xue, Y., Qin, R., Wang, X., Wu, S., Zhu, J., Li, Y. S., Zhang, C., & Wei, Y. (2025). Advances in the study of epithelial mesenchymal transition in cancer progression: Role of miRNAs. Progress in Biophysics and Molecular Biology, 196, 69\u201390. https:\/\/doi.org\/10.1016\/j.pbiomolbio.2025.04.001","journal-title":"Progress in Biophysics and Molecular Biology"},{"issue":"1","key":"11057_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-021-00206-5","volume":"10","author":"B Dong","year":"2021","unstructured":"Dong, B., Li, S., Zhu, S., Yi, M., Luo, S., & Wu, K. (2021). MiRNA-mediated EMT and CSCs in cancer chemoresistance. Experimental Hematology & Oncology, 10(1), Article 12. https:\/\/doi.org\/10.1186\/s40164-021-00206-5","journal-title":"Experimental Hematology & Oncology"},{"issue":"1","key":"11057_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00888-2","volume":"20","author":"X Chen","year":"2022","unstructured":"Chen, X., Yang, M., Yin, J., Li, P., Zeng, S., Zheng, G., He, Z., Liu, H., Wang, Q., Zhang, F., & Chen, D. (2022). Tumor-associated macrophages promote epithelial-mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2\/AKT\/\u03b2-catenin signaling. Cell Communication and Signaling, 20(1), Article 92. https:\/\/doi.org\/10.1186\/s12964-022-00888-2","journal-title":"Cell Communication and Signaling"},{"key":"11057_CR82","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bbrc.2022.04.126","volume":"613","author":"X Chen","year":"2022","unstructured":"Chen, X., Yang, G., Liu, M., Quan, Z., Wang, L., Luo, C., Wu, X., & Zheng, Y. (2022). Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT\/EZH2\/ androgen receptor signaling pathway. Biochemical and Biophysical Research Communications, 613, 53\u201360. https:\/\/doi.org\/10.1016\/j.bbrc.2022.04.126","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"11057_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1417201","volume":"15","author":"ZN Lei","year":"2024","unstructured":"Lei, Z. N., Teng, Q. X., Koya, J., Liu, Y., Chen, Z., Zeng, L., Chen, Z. S., Fang, S., Wang, J., Liu, Y., & Pan, Y. (2024). The correlation between cancer stem cells and epithelial-mesenchymal transition: Molecular mechanisms and significance in cancer theragnosis. Frontiers In Immunology, 15, Article 1417201. https:\/\/doi.org\/10.3389\/fimmu.2024.1417201","journal-title":"Frontiers In Immunology"},{"issue":"43","key":"11057_CR84","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1038\/s41388-024-03156-4","volume":"43","author":"W Fernando","year":"2024","unstructured":"Fernando, W., Cruickshank, B. M., Arun, R. P., MacLean, M. R., Cahill, H. F., Morales-Quintanilla, F., Dean, C. A., Wasson, M. D., Dahn, M. L., Coyle, K. M., Walker, O. L., Power Coombs, M. R., & Marcato, P. (2024). ALDH1A3 is the switch that determines the balance of ALDH+ and CD24-CD44+ cancer stem cells, EMT-MET, and glucose metabolism in breast cancer. Oncogene, 43(43), 3151\u20133169. https:\/\/doi.org\/10.1038\/s41388-024-03156-4","journal-title":"Oncogene"},{"key":"11057_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101276","volume":"83","author":"M Jiang","year":"2025","unstructured":"Jiang, M., Wang, J., Li, Y., Zhang, K., Wang, T., Bo, Z., Lu, S., Rodr\u00edguez, R. A., Wei, R., Zhu, M., Nicot, C., & Sethi, G. (2025). EMT and cancer stem cells: Drivers of therapy resistance and promising therapeutic targets. Drug Resistance Updates, 83, Article 101276. https:\/\/doi.org\/10.1016\/j.drup.2025.101276","journal-title":"Drug Resistance Updates"},{"key":"11057_CR86","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.canlet.2017.03.008","volume":"396","author":"Y Li","year":"2017","unstructured":"Li, Y., Atkinson, K., & Zhang, T. (2017). Combination of chemotherapy and cancer stem cell targeting agents: Preclinical and clinical studies. Cancer Letters, 396, 103\u2013109. https:\/\/doi.org\/10.1016\/j.canlet.2017.03.008","journal-title":"Cancer Letters"},{"issue":"4","key":"11057_CR87","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41416-019-0683-3","volume":"122","author":"A De Jesus-Acosta","year":"2020","unstructured":"De Jesus-Acosta, A., Sugar, E. A., O\u2019Dwyer, P. J., Ramanathan, R. K., Von Hoff, D. D., Rasheed, Z., Zheng, L., Begum, A., Anders, R., Maitra, A., McAllister, F., Rajeshkumar, N. V., Yabuuchi, S., de Wil, R. F., Batukbhai, B., Sahin, I., & Laheru, D. A. (2020). Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. British Journal of Cancer, 122(4), 498\u2013505. https:\/\/doi.org\/10.1038\/s41416-019-0683-3","journal-title":"British Journal of Cancer"},{"issue":"23","key":"11057_CR88","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari, R., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017). Combination therapy in combating cancer. Oncotarget, 8(23), 38022\u201338043. https:\/\/doi.org\/10.18632\/oncotarget.16723","journal-title":"Oncotarget"},{"issue":"4","key":"11057_CR89","doi-asserted-by":"publisher","first-page":"235","DOI":"10.32604\/or.2022.025323","volume":"29","author":"ZN Navaei","year":"2022","unstructured":"Navaei, Z. N., Khalili-Tanha, G., Zangouei, A. S., Abbaszadegan, M. R., & Moghbeli, M. (2022). PI3K\/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cells. Oncology Research, 29(4), 235\u2013250. https:\/\/doi.org\/10.32604\/or.2022.025323","journal-title":"Oncology Research"},{"issue":"1","key":"11057_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00838-y","volume":"20","author":"MJ Ansari","year":"2022","unstructured":"Ansari, M. J., Bokov, D., Markov, A., Jalil, A. T., Shalaby, M. N., Suksatan, W., Chupradit, S., Al-Ghamdi, H. S., Shomali, N., Zamani, A., Mohammadi, A., & Dadashpour, M. (2022). Cancer combination therapies by angiogenesis inhibitors; A comprehensive review. Cell Communication and Signaling, 20(1), Article 49. https:\/\/doi.org\/10.1186\/s12964-022-00838-y","journal-title":"Cell Communication and Signaling"},{"issue":"6","key":"11057_CR91","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1054\/drup.2000.0165","volume":"3","author":"MA Shah","year":"2000","unstructured":"Shah, M. A., & Schwartz, G. K. (2000). The relevance of drug sequence in combination chemotherapy. Drug Resistance Updates, 3(6), 335\u2013356. https:\/\/doi.org\/10.1054\/drup.2000.0165","journal-title":"Drug Resistance Updates"},{"key":"11057_CR92","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00086","volume":"3","author":"C Hu","year":"2019","unstructured":"Hu, C., & Dignam, J. J. (2019). Biomarker-driven oncology clinical trials: Key design elements, types, features, and practical considerations. JCO Precision Oncology, 3, Article PO.19.00086. https:\/\/doi.org\/10.1200\/PO.19.00086","journal-title":"JCO Precision Oncology"},{"key":"11057_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110009","volume":"125","author":"SS Bashraheel","year":"2020","unstructured":"Bashraheel, S. S., Domling, A., & Goda, S. K. (2020). Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine. Biomedicine & Pharmacotherapy, 125, Article 110009. https:\/\/doi.org\/10.1016\/j.biopha.2020.110009","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"1","key":"11057_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03748-4","volume":"25","author":"YJ Zhu","year":"2025","unstructured":"Zhu, Y. J., Li, S. Y., Yang, S. S., Du, Y., Zhang, Z. Y., & Liu, J. Y. (2025). CD44 on cancer stem cell is a potential immunological and prognostic pan-cancer biomarker. Cancer Cell International, 25(1), Article 134. https:\/\/doi.org\/10.1186\/s12935-025-03748-4","journal-title":"Cancer Cell International"},{"issue":"21","key":"11057_CR95","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1038\/onc.2016.452","volume":"36","author":"C Kerr","year":"2017","unstructured":"Kerr, C., Szmacinski, H., Fisher, M. L., Nance, B., Lakowicz, J. R., Akbar, A., Keillor, J. W., Lok Wong, T., Godoy-Ruiz, R., Toth, E. A., Weber, D. J., & Eckert, R. L. (2017). Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival. Oncogene, 36(21), 2981\u20132990. https:\/\/doi.org\/10.1038\/onc.2016.452","journal-title":"Oncogene"},{"issue":"3","key":"11057_CR96","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.bbrc.2015.06.137","volume":"468","author":"SS Kim","year":"2015","unstructured":"Kim, S. S., Harford, J. B., Pirollo, K. F., & Chang, E. H. (2015). Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine. Biochemical and Biophysical Research Communications, 468(3), 485\u2013489. https:\/\/doi.org\/10.1016\/j.bbrc.2015.06.137","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"11057_CR97","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1615\/CritRevOncog.2016016976","volume":"21","author":"AR Safa","year":"2016","unstructured":"Safa, A. R. (2016). Resistance to cell death and its modulation in cancer stem cells. Critical Reviews\u2122 in Oncogenesis, 21, 203\u2013219. https:\/\/doi.org\/10.1615\/CritRevOncog.2016016976","journal-title":"Critical Reviews\u2122 in Oncogenesis"},{"key":"11057_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01509","volume":"8","author":"S Santamaria","year":"2017","unstructured":"Santamaria, S., Delgado, M., Kremer, L., & Garcia-Sanz, J. A. (2017). Will a mAb-based immunotherapy directed against cancer stem cells be feasible? Frontiers in Immunology, 8, Article 1509. https:\/\/doi.org\/10.3389\/fimmu.2017.01509","journal-title":"Frontiers in Immunology"},{"issue":"6","key":"11057_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/toxins8060165","volume":"8","author":"JU Schmohl","year":"2016","unstructured":"Schmohl, J. U., & Vallera, D. A. (2016). CD133, selectively targeting the root of cancer. Toxins, 8(6), Article 165. https:\/\/doi.org\/10.3390\/toxins8060165","journal-title":"Toxins"},{"key":"11057_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-152","volume":"12","author":"S Ganapathy-Kanniappan","year":"2013","unstructured":"Ganapathy-Kanniappan, S., & Geschwind, J. F. (2013). Tumor glycolysis as a target for cancer therapy: Progress and prospects. Molecular Cancer, 12, Article 152. https:\/\/doi.org\/10.1186\/1476-4598-12-152","journal-title":"Molecular Cancer"},{"issue":"1","key":"11057_CR101","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., Norris, A., Sanseau, P., Cavalla, D., & Pirmohamed, M. (2019). Drug repurposing: Progress, challenges and recommendations. Nature Reviews. Drug Discovery, 18(1), 41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"7","key":"11057_CR102","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/bjc.2013.534","volume":"109","author":"P Liu","year":"2013","unstructured":"Liu, P., Kumar, I. S., Brown, S., Kannappan, V., Tawari, P. E., Tang, J. Z., Jiang, W., Armesilla, A. L., Darling, J. L., & Wang, W. (2013). Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. British Journal of Cancer, 109(7), 1876\u20131885. https:\/\/doi.org\/10.1038\/bjc.2013.534","journal-title":"British Journal of Cancer"},{"key":"11057_CR103","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.ejmech.2017.12.039","volume":"144","author":"A Rejhov\u00e1","year":"2018","unstructured":"Rejhov\u00e1, A., Opattov\u00e1, A., \u010cumov\u00e1, A., Sl\u00edva, D., & Vodi\u010dka, P. (2018). Natural compounds and combination therapy in colorectal cancer treatment. European Journal of Medicinal Chemistry, 144, 582\u2013594. https:\/\/doi.org\/10.1016\/j.ejmech.2017.12.039","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"4","key":"11057_CR104","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.molcel.2012.06.014","volume":"47","author":"H Korkaya","year":"2012","unstructured":"Korkaya, H., Kim, G., Davis, A., Malik, F., Henry, N. L., Ithimakin, S., Quraishi, A. A., Tawakkol, N., D\u2019Angelo, R., Paulson, A. K., Chung, S., Luther, T., Paholak, H. J., Liu, S., Hassan, K. A., Zen, Q., Clouthier, S. G., & Wicha, M. S. (2012). Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Molecular Cell, 47(4), 570\u2013584. https:\/\/doi.org\/10.1016\/j.molcel.2012.06.014","journal-title":"Molecular Cell"},{"key":"11057_CR105","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.canlet.2017.02.023","volume":"394","author":"JP Burnett","year":"2017","unstructured":"Burnett, J. P., Lim, G., Li, Y., Shah, R. B., Lim, R., Paholak, H. J., McDermott, S. P., Sun, L., Tsume, Y., Bai, S., Wicha, M. S., Sun, D., & Zhang, T. (2017). Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells. Cancer Letters, 394, 52\u201364. https:\/\/doi.org\/10.1016\/j.canlet.2017.02.023","journal-title":"Cancer Letters"},{"issue":"3","key":"11057_CR106","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/carcin\/bgv006","volume":"36","author":"S Toden","year":"2015","unstructured":"Toden, S., Okugawa, Y., Jascur, T., Wodarz, D., Komarova, N. L., Buhrmann, C., Shakibaei, M., Boland, C. R., & Goel, A. (2015). Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. Carcinogenesis, 36(3), 355\u2013367. https:\/\/doi.org\/10.1093\/carcin\/bgv006","journal-title":"Carcinogenesis"},{"issue":"3","key":"11057_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032122","volume":"24","author":"M Kim","year":"2023","unstructured":"Kim, M., Bakyt, L., Akhmetkaliyev, A., Toktarkhanova, D., & Bulanin, D. (2023). Re-sensitizing cancer stem cells to conventional chemotherapy agents. International Journal of Molecular Sciences, 24(3), Article 2122. https:\/\/doi.org\/10.3390\/ijms24032122","journal-title":"International Journal of Molecular Sciences"},{"key":"11057_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-017-0008-3","author":"PV Deraska","year":"2018","unstructured":"Deraska, P. V., O\u2019Leary, C., Reavis, H. D., Labe, S., Dinh, T., Lazaro, J., Sweeney, C., D\u2019Andrea, A. D., & Kozono, D. (2018). NF-\u03baB inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair. Cell Death Discovery. https:\/\/doi.org\/10.1038\/s41420-017-0008-3","journal-title":"Cell Death Discovery"},{"issue":"3","key":"11057_CR109","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/med.21870","volume":"42","author":"D Qi","year":"2021","unstructured":"Qi, D., Liu, Y., Li, J., Huang, J. H., Hu, X., & Wu, E. (2021). Salinomycin as a potent anticancer stem cell agent: State of the art and future directions. Medicinal Research Reviews, 42(3), 1037\u20131063. https:\/\/doi.org\/10.1002\/med.21870","journal-title":"Medicinal Research Reviews"},{"issue":"12","key":"11057_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125632","volume":"26","author":"H Bousbaa","year":"2025","unstructured":"Bousbaa, H., Cidade, H., & Silva, P. M. A. (2025). Advances in bioactive compounds and cancer therapy-insights from the special issue \u201cBioactive compounds in cancers.\u201d International Journal of Molecular Sciences, 26(12), Article 5632. https:\/\/doi.org\/10.3390\/ijms26125632","journal-title":"International Journal of Molecular Sciences"},{"issue":"9","key":"11057_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27093036","volume":"27","author":"K Mazumder","year":"2022","unstructured":"Mazumder, K., Aktar, A., Roy, P., Biswas, B., Hossain, M. E., Sarkar, K. K., Bachar, S. C., Ahmed, F., Monjur-Al-Hossain, A. S. M., & Fukase, K. (2022). A review on mechanistic insight of plant derived anticancer bioactive phytocompounds and their structure activity relationship. Molecules, 27(9), Article 3036. https:\/\/doi.org\/10.3390\/molecules27093036","journal-title":"Molecules"},{"key":"11057_CR112","doi-asserted-by":"publisher","DOI":"10.37349\/eds.2025.1008106","author":"JK Opara","year":"2025","unstructured":"Opara, J. K., et al. (2025). Natural products targeting cancer stem cells: A promising therapeutic approach. Exploration of Drug Science. https:\/\/doi.org\/10.37349\/eds.2025.1008106","journal-title":"Exploration of Drug Science"},{"key":"11057_CR113","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.canlet.2018.06.034","volume":"433","author":"MM Chan","year":"2018","unstructured":"Chan, M. M., Chen, R., & Fong, D. (2018). Targeting cancer stem cells with dietary phytochemical - Repositioned drug combinations. Cancer Letters, 433, 53\u201364. https:\/\/doi.org\/10.1016\/j.canlet.2018.06.034","journal-title":"Cancer Letters"},{"issue":"7","key":"11057_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/ph14070676","volume":"14","author":"PK Gupta","year":"2021","unstructured":"Gupta, P. K., Saraff, M., Gahtori, R., Negi, N., Tripathi, S. K., Kumar, J., Kumar, S., Aldhayan, S. H., Dhanasekaran, S., Abomughaid, M. M., Dua, K., Gundamaraju, R., Ojha, S., Ruokolainen, J., Jha, N. K., & Kesari, K. K. (2021). Phytomedicines targeting cancer stem cells: Therapeutic opportunities and prospects for pharmaceutical development. Pharmaceuticals (Basel), 14(7), Article 676. https:\/\/doi.org\/10.3390\/ph14070676","journal-title":"Pharmaceuticals (Basel)"},{"issue":"24","key":"11057_CR115","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246203","volume":"14","author":"ST Asma","year":"2022","unstructured":"Asma, S. T., Acaroz, U., Imre, K., Morar, A., Shah, S. R. A., Hussain, S. Z., Arslan-Acaroz, D., Demirbas, H., Hajrulai-Musliu, Z., Istanbullugil, F. R., Soleimanzadeh, A., Morozov, D., Zhu, K., Herman, V., Ayad, A., Athanassiou, C., & Ince, S. (2022). Natural products\/bioactive compounds as a source of anticancer drugs. Cancers, 14(24), Article 6203. https:\/\/doi.org\/10.3390\/cancers14246203","journal-title":"Cancers"},{"key":"11057_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113384","volume":"153","author":"A Esmeeta","year":"2022","unstructured":"Esmeeta, A., Adhikary, S., Dharshnaa, V., Swarnamughi, P., Ummul Maqsummiya, Z., Banerjee, A., Pathak, S., & Duttaroy, A. K. (2022). Plant-derived bioactive compounds in colon cancer treatment: An updated review. Biomedicine & Pharmacotherapy, 153, Article 113384. https:\/\/doi.org\/10.1016\/j.biopha.2022.113384","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"11057_CR117","doi-asserted-by":"crossref","unstructured":"Debnath, I., & Kundu, M. (2025). Therapeutic potential of natural compounds in targeting cancer stem cells: A promising approach for cancer treatment. Discover Oncology, 16(1), 1433.","DOI":"10.1007\/s12672-025-03190-y"},{"issue":"11\u201312","key":"11057_CR118","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.nut.2014.02.016","volume":"30","author":"M Kasdagly","year":"2014","unstructured":"Kasdagly, M., Radhakrishnan, S., Reddivari, L., Veeramachaneni, D. N., & Vanamala, J. (2014). Colon carcinogenesis: Influence of Western diet-induced obesity and targeting stem cells using dietary bioactive compounds. Nutrition (Burbank, Los Angeles County, Calif.), 30(11\u201312), 1242\u20131256. https:\/\/doi.org\/10.1016\/j.nut.2014.02.016","journal-title":"Nutrition (Burbank, Los Angeles County, Calif.)"},{"issue":"2","key":"11057_CR119","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.canlet.2015.05.005","volume":"364","author":"MI James","year":"2015","unstructured":"James, M. I., Iwuji, C., Irving, G., Karmokar, A., Higgins, J. A., Griffin-Teal, N., Thomas, A., Greaves, P., Cai, H., Patel, S. R., Morgan, B., Dennison, A., Metcalfe, M., Garcea, G., Lloyd, D. M., Berry, D. P., Steward, W. P., Howells, L. M., & Brown, K. (2015). Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. Cancer Letters, 364(2), 135\u2013141. https:\/\/doi.org\/10.1016\/j.canlet.2015.05.005","journal-title":"Cancer Letters"},{"issue":"7","key":"11057_CR120","first-page":"1894","volume":"7","author":"RA Sharma","year":"2001","unstructured":"Sharma, R. A., McLelland, H. R., Hill, K. A., Ireson, C. R., Euden, S. A., Manson, M. M., Pirmohamed, M., Marnett, L. J., Gescher, A. J., & Steward, W. P. (2001). Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clinical Cancer Research\u202f: An Official Journal of the American Association for Cancer Research, 7(7), 1894\u20131900.","journal-title":"Clinical Cancer Research\u202f: An Official Journal of the American Association for Cancer Research"},{"issue":"7","key":"11057_CR121","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/jn\/nxz029","volume":"149","author":"LM Howells","year":"2019","unstructured":"Howells, L. M., Iwuji, C. O. O., Irving, G. R. B., Barber, S., Walter, H., Sidat, Z., Griffin-Teall, N., Singh, R., Foreman, N., Patel, S. R., Morgan, B., Steward, W. P., Gescher, A., Thomas, A. L., & Brown, K. (2019). Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase IIa trial. Journal of Nutrition, 149(7), 1133\u20131139. https:\/\/doi.org\/10.1093\/jn\/nxz029","journal-title":"Journal of Nutrition"},{"issue":"5","key":"11057_CR122","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00280-020-04059-3","volume":"85","author":"A Kawazoe","year":"2020","unstructured":"Kawazoe, A., Kuboki, Y., Bando, H., Fukuoka, S., Kojima, T., Naito, Y., Iino, S., Yodo, Y., Doi, T., Shitara, K., & Yoshino, T. (2020). Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 85(5), 855\u2013862. https:\/\/doi.org\/10.1007\/s00280-020-04059-3","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"1","key":"11057_CR123","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.clcc.2022.11.002","volume":"22","author":"MA Shah","year":"2022","unstructured":"Shah, M. A., Yoshino, T., Tebbutt, N. C., Grothey, A., Tabernero, J., Xu, R., Cervantes, A., Oh, S. C., Yamaguchi, K., Fakih, M., Falcone, A., Wu, C., Chiu, V. K., Tomasek, J., Bendell, J., Fontaine, M., Hitron, M., Xu, B., Taieb, J., & Van Cutsem, E. (2022). Napabucasin plus FOLFIRI in patients with previously treated metastatic colorectal cancer: Results from the open-label, randomized phase III CANSTEM303C study. Clinical Colorectal Cancer, 22(1), 100\u2013110.","journal-title":"Clinical Colorectal Cancer"},{"key":"11057_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101897","volume":"58","author":"T Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab, T., Okusaka, T., Goldstein, D., Oh, D., Ueno, M., Ioka, T., Fang, W., Anderson, E. C., Noel, M. S., Reni, M., Choi, H. J., Goldberg, J. S., Oh, S. C., Li, C., Tabernero, J., Li, J., Foos, E., Oh, C., & Van Cutsem, E. (2023). Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: An adaptive multicentre, randomised, open-label, phase 3, superiority trial. EClinicalMedicine, 58, Article 101897. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101897","journal-title":"EClinicalMedicine"},{"key":"11057_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/950658","volume":"2012","author":"C Naujokat","year":"2012","unstructured":"Naujokat, C., & Steinhart, R. (2012). Salinomycin as a drug for targeting human cancer stem cells. Journal of Biomedicine and Biotechnology, 2012, 1\u201317. https:\/\/doi.org\/10.1155\/2012\/950658","journal-title":"Journal of Biomedicine and Biotechnology"},{"key":"11057_CR126","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cbi.2015.08.007","volume":"240","author":"K Resham","year":"2015","unstructured":"Resham, K., Patel, P. N., Thummuri, D., Guntuku, L., Shah, V., Bambal, R. B., & Naidu, V. G. M. (2015). Preclinical drug metabolism and pharmacokinetics of salinomycin, a potential candidate for targeting human cancer stem cells. Chemico-Biological Interactions, 240, 146\u2013152.","journal-title":"Chemico-Biological Interactions"},{"issue":"2","key":"11057_CR127","first-page":"2495","volume":"16","author":"G Zhang","year":"2018","unstructured":"Zhang, G., Zhang, S., Ren, J., Yao, C., Zhao, Z., Qi, X., Zhang, X., Wang, S., & Li, L. (2018). Salinomycin may inhibit the cancer stem-like populations with increased chemoradioresistance that nasopharyngeal cancer tumorspheres contain. Oncology Letters, 16(2), 2495\u20132500.","journal-title":"Oncology Letters"},{"issue":"6","key":"11057_CR128","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","volume":"149","author":"H Clevers","year":"2012","unstructured":"Clevers, H., & Nusse, R. (2012). Wnt\/\u03b2-catenin signaling and disease. Cell, 149(6), 1192\u20131205. https:\/\/doi.org\/10.1016\/j.cell.2012.05.012","journal-title":"Cell"},{"issue":"4","key":"11057_CR129","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nrc3458","volume":"13","author":"KF Harvey","year":"2013","unstructured":"Harvey, K. F., Zhang, X., & Thomas, D. M. (2013). The hippo pathway and human cancer. Nature Reviews. Cancer, 13(4), 246\u2013257. https:\/\/doi.org\/10.1038\/nrc3458","journal-title":"Nature Reviews. Cancer"},{"issue":"3","key":"11057_CR130","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ccr.2014.02.018","volume":"25","author":"P Ntziachristos","year":"2014","unstructured":"Ntziachristos, P., Lim, J. S., Sage, J., & Aifantis, I. (2014). From fly wings to targeted cancer therapies: A centennial for notch signaling. Cancer Cell, 25(3), 318\u2013334. https:\/\/doi.org\/10.1016\/j.ccr.2014.02.018","journal-title":"Cancer Cell"},{"issue":"5","key":"11057_CR131","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a000141","volume":"1","author":"M Karin","year":"2009","unstructured":"Karin, M. (2009). NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harbor Perspectives in Biology, 1(5), Article a000141. https:\/\/doi.org\/10.1101\/cshperspect.a000141","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"2","key":"11057_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/cancers8020022","volume":"8","author":"TK Rimkus","year":"2016","unstructured":"Rimkus, T. K., Carpenter, R. L., Qasem, S., Chan, M., & Lo, H. W. (2016). Targeting the sonic hedgehog signaling pathway: Review of smoothened and GLI inhibitors. Cancers, 8(2), Article 22. https:\/\/doi.org\/10.3390\/cancers8020022","journal-title":"Cancers"},{"key":"11057_CR133","doi-asserted-by":"crossref","unstructured":"Porta, C., Paglino, C., & Mosca, A. (2014). Targeting PI3K\/Akt\/mTOR signaling in cancer.Frontiers in oncology, 4, 64.","DOI":"10.3389\/fonc.2014.00064"},{"issue":"1","key":"11057_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00901-6","volume":"13","author":"Y Yang","year":"2020","unstructured":"Yang, Y., Li, X., Wang, T., Guo, Q., Xi, T., & Zheng, L. (2020). Emerging agents that target signaling pathways in cancer stem cells. Journal of Hematology & Oncology, 13(1), Article 60. https:\/\/doi.org\/10.1186\/s13045-020-00901-6","journal-title":"Journal of Hematology & Oncology"},{"key":"11057_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.65077","volume":"9","author":"V Kumar","year":"2021","unstructured":"Kumar, V., Vashishta, M., Kong, L., Wu, X., Lu, J. J., Guha, C., & Dwarakanath, B. S. (2021). The role of Notch, Hedgehog, and Wnt signaling pathways in the resistance of tumors to anticancer therapies. Frontiers in Cell and Developmental Biology, 9, Article 650772. https:\/\/doi.org\/10.3389\/fcell.2021.65077","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"3\u20134","key":"11057_CR136","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10555-009-9187-6","volume":"28","author":"WD Brandt","year":"2009","unstructured":"Brandt, W. D., Matsui, W., Rosenberg, J. E., He, X., Ling, S., Schaeffer, E. M., & Berman, D. M. (2009). Urothelial carcinoma: Stem cells on the edge. Cancer and Metastasis Reviews, 28(3\u20134), 291\u2013304. https:\/\/doi.org\/10.1007\/s10555-009-9187-6","journal-title":"Cancer and Metastasis Reviews"},{"issue":"5","key":"11057_CR137","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.375","volume":"4","author":"L Lv","year":"2023","unstructured":"Lv, L., & Zhou, X. (2023). Targeting hippo signaling in cancer: Novel perspectives and therapeutic potential. MedComm, 4(5), Article e375. https:\/\/doi.org\/10.1002\/mco2.375","journal-title":"MedComm"},{"issue":"1","key":"11057_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00701-5","volume":"6","author":"F Yu","year":"2021","unstructured":"Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021). Wnt\/\u03b2-catenin signaling in cancers and targeted therapies. Signal Transduction and Targeted Therapy, 6(1), Article 307. https:\/\/doi.org\/10.1038\/s41392-021-00701-5","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"16","key":"11057_CR139","doi-asserted-by":"publisher","first-page":"15311","DOI":"10.1007\/s00432-023-05272-2","volume":"149","author":"H Shi","year":"2023","unstructured":"Shi, H., Zou, Y., Zhong, W., Li, Z., Wang, X., Yin, Y., Li, D., Liu, Y., & Li, M. (2023). Complex roles of Hippo-YAP\/TAZ signaling in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 149(16), 15311\u201315322. https:\/\/doi.org\/10.1007\/s00432-023-05272-2","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"1","key":"11057_CR140","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-024-01563-4","volume":"17","author":"P Song","year":"2024","unstructured":"Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X. (2024). Wnt\/\u03b2-catenin signaling pathway in carcinogenesis and cancer therapy. Journal of Hematology & Oncology, 17(1), 46. https:\/\/doi.org\/10.1186\/s13045-024-01563-4","journal-title":"Journal of Hematology & Oncology"},{"issue":"8","key":"11057_CR141","doi-asserted-by":"publisher","DOI":"10.3390\/cells9081879","volume":"9","author":"CT Meisel","year":"2020","unstructured":"Meisel, C. T., Porcheri, C., & Mitsiadis, T. A. (2020). Cancer stem cells, quo vadis? The Notch signaling pathway in tumor initiation and progression. Cells, 9(8), Article 1879. https:\/\/doi.org\/10.3390\/cells9081879","journal-title":"Cells"},{"issue":"3","key":"11057_CR142","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2024.5676","volume":"65","author":"S Li","year":"2024","unstructured":"Li, S., Hao, L., Li, N., Hu, X., Yan, H., Dai, E., & Shi, X. (2024). Targeting the Hippo\/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (review). International Journal of Oncology, 65(3), Article 88. https:\/\/doi.org\/10.3892\/ijo.2024.5676","journal-title":"International Journal of Oncology"},{"key":"11057_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108179","volume":"238","author":"DJ Flanagan","year":"2022","unstructured":"Flanagan, D. J., Woodcock, S. A., Phillips, C., Eagle, C., & Sansom, O. J. (2022). Targeting ligand-dependent Wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibition. Pharmacology & Therapeutics, 238, Article 108179. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108179","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"11057_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01851-y","volume":"9","author":"X Chu","year":"2024","unstructured":"Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024). Cancer stem cells: Advances in knowledge and implications for cancer therapy. Signal Transduction and Targeted Therapy, 9(1), Article 170. https:\/\/doi.org\/10.1038\/s41392-024-01851-y","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"4","key":"11057_CR145","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00280-012-2043-3","volume":"71","author":"HA Burris","year":"2013","unstructured":"Burris, H. A. (2013). Overcoming acquired resistance to anticancer therapy: Focus on the PI3K\/AKT\/mTOR pathway. Cancer Chemotherapy and Pharmacology, 71(4), 829\u2013842. https:\/\/doi.org\/10.1007\/s00280-012-2043-3","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"5","key":"11057_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167164","volume":"1870","author":"M Masoudi","year":"2024","unstructured":"Masoudi, M., Moti, D., Masoudi, R., Auwal, A., Hossain, M. M., Pronoy, T. U. H., Rashel, K. M., Gopalan, V., & Islam, F. (2024). Metabolic adaptations in cancer stem cells: A key to therapy resistance. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1870(5), Article 167164. https:\/\/doi.org\/10.1016\/j.bbadis.2024.167164","journal-title":"Biochimica et Biophysica Acta - Molecular Basis of Disease"},{"issue":"6","key":"11057_CR147","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.3390\/cimb46060323","volume":"46","author":"C Berrino","year":"2024","unstructured":"Berrino, C., & Omar, A. (2024). Unravelling the mysteries of the sonic hedgehog pathway in cancer stem cells: Activity, crosstalk and regulation. Current Issues in Molecular Biology, 46(6), 5397\u20135419. https:\/\/doi.org\/10.3390\/cimb46060323","journal-title":"Current Issues in Molecular Biology"},{"issue":"1","key":"11057_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01559-5","volume":"8","author":"J Jing","year":"2023","unstructured":"Jing, J., Wu, Z., Wang, J., Luo, G., Lin, H., Fan, Y., & Zhou, C. (2023). Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies. Signal Transduction and Targeted Therapy, 8(1), Article 315. https:\/\/doi.org\/10.1038\/s41392-023-01559-5","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"1","key":"11057_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01812-6","volume":"22","author":"R Liu","year":"2024","unstructured":"Liu, R., Yu, Y., Wang, Q., Zhao, Q., Yao, Y., Sun, M., Zhuang, J., Sun, C., & Qi, Y. (2024). Interactions between hedgehog signaling pathway and the complex tumor microenvironment in breast cancer: Current knowledge and therapeutic promises. Cell Communication and Signaling, 22(1), Article 432. https:\/\/doi.org\/10.1186\/s12964-024-01812-6","journal-title":"Cell Communication and Signaling"},{"key":"11057_CR150","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.2147\/OTT.S108171","volume":"9","author":"HQ Doan","year":"2016","unstructured":"Doan, H. Q., Silapunt, S., & Migden, M. R. (2016). Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma. OncoTargets and Therapy, 9, 5671\u20135678. https:\/\/doi.org\/10.2147\/OTT.S108171","journal-title":"OncoTargets and Therapy"},{"issue":"10","key":"11057_CR151","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1016\/j.celrep.2017.11.025","volume":"21","author":"JL Regan","year":"2017","unstructured":"Regan, J. L., Schumacher, D., Staudte, S., Steffen, A., Haybaeck, J., Keilholz, U., Schweiger, C., Golob-Schwarzl, N., Mumberg, D., Henderson, D., Lehrach, H., Regenbrecht, C. R. A., Sch\u00e4fer, R., & Lange, M. (2017). Non-canonical hedgehog signaling is a positive regulator of the WNT pathway and is required for the survival of colon cancer stem cells. Cell Reports, 21(10), 2813\u20132828. https:\/\/doi.org\/10.1016\/j.celrep.2017.11.025","journal-title":"Cell Reports"},{"issue":"4","key":"11057_CR152","doi-asserted-by":"publisher","first-page":"408","DOI":"10.7150\/jca.13305","volume":"7","author":"F Wang","year":"2016","unstructured":"Wang, F., Ma, L., Zhang, Z., Liu, X., Gao, H., Zhuang, Y., Yang, P., Kornmann, M., Tian, X., & Yang, Y. (2016). Hedgehog signaling regulates epithelial-mesenchymal transition in pancreatic cancer stem-like cells. Journal of Cancer, 7(4), 408\u2013417. https:\/\/doi.org\/10.7150\/jca.13305","journal-title":"Journal of Cancer"},{"issue":"5","key":"11057_CR153","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3978\/j.issn.2218-676X.2013.08.01","volume":"2","author":"J Wang","year":"2013","unstructured":"Wang, J., Ma, Y., & Cooper, M. K. (2013). Cancer stem cells in glioma: Challenges and opportunities. Translational Cancer Research, 2(5), 429\u2013441. https:\/\/doi.org\/10.3978\/j.issn.2218-676X.2013.08.01","journal-title":"Translational Cancer Research"},{"key":"11057_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/srep36796","volume":"6","author":"X Wang","year":"2016","unstructured":"Wang, X., Li, Y., Dai, Y., et al. (2016). Sulforaphane improves chemotherapy efficacy by targeting cancer stem cell-like properties via the miR-124\/IL-6R\/STAT3 axis. Scientific Reports, 6, Article 36796. https:\/\/doi.org\/10.1038\/srep36796","journal-title":"Scientific Reports"},{"issue":"9","key":"11057_CR155","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.7150\/jca.73143","volume":"13","author":"L Yao","year":"2022","unstructured":"Yao, L., & Zhang, X. (2022). Interaction between prostate cancer stem cells and bone microenvironment regulates prostate cancer bone metastasis and treatment resistance. Journal of Cancer, 13(9), 2757\u20132767. https:\/\/doi.org\/10.7150\/jca.73143","journal-title":"Journal of Cancer"},{"issue":"1","key":"11057_CR156","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., Kulke, M. H., Baird, R. D., Prabhu, J. S., Carbone, D., Pecoraro, C., Teh, D. B. L., Sethi, G., Cavalieri, V., Lin, K. H., \u2026 Kumar, A. P. (2023). PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Molecular Cancer, 22(1), Article 138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6","journal-title":"Molecular Cancer"},{"issue":"4","key":"11057_CR157","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.soc.2013.06.008","volume":"22","author":"B Hassan","year":"2013","unstructured":"Hassan, B., Akcakanat, A., Holder, A. M., & Meric-Bernstam, F. (2013). Targeting the PI3-kinase\/Akt\/mTOR signaling pathway. Surgical Oncology Clinics of North America, 22(4), 641\u2013664. https:\/\/doi.org\/10.1016\/j.soc.2013.06.008","journal-title":"Surgical Oncology Clinics of North America"},{"issue":"1","key":"11057_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021). Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduction and Targeted Therapy, 6(1), Article 425. https:\/\/doi.org\/10.1038\/s41392-021-00828-5","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"21","key":"11057_CR159","doi-asserted-by":"publisher","DOI":"10.3390\/nu16213741","volume":"16","author":"N Or\u0161oli\u0107","year":"2024","unstructured":"Or\u0161oli\u0107, N., & Jazvin\u0161\u0107ak Jembrek, M. (2024). Potential strategies for overcoming drug resistance pathways using propolis and its polyphenolic\/flavonoid compounds in combination with chemotherapy and radiotherapy. Nutrients, 16(21), Article 3741. https:\/\/doi.org\/10.3390\/nu16213741","journal-title":"Nutrients"},{"issue":"7","key":"11057_CR160","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.21873\/anticanres.15820","volume":"42","author":"X Zhao","year":"2022","unstructured":"Zhao, X., Ma, B., Zhu, H., Bai, J., Liu, L., Li, X., Cai, J., Wang, B., Wang, L., Pang, Y., Zhang, H., Yang, Y. I., Li, N., & Chen, M. (2022). PI3K\/Akt and Wnt\/\u03b2-catenin signaling cross-regulate NF-\u03baB signaling in TNF-\u03b1-induced human Lgr5+ intestinal stem cells. Anticancer Research, 42(7), 3325\u20133340. https:\/\/doi.org\/10.21873\/anticanres.15820","journal-title":"Anticancer Research"},{"key":"11057_CR161","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04297-3","author":"KS Prabhu","year":"2025","unstructured":"Prabhu, K. S., Kuttikrishnan, S., Mariyam, Z., Habeeba, U., Panicker, A. J., Masoodi, T., Junejo, K., & Uddin, S. (2025). PI3 K\/AKT\/mTOR pathway and its role in breast cancer stem cells. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology. https:\/\/doi.org\/10.1007\/s00210-025-04297-3","journal-title":"Naunyn-Schmiedeberg's Archives of Pharmacology"},{"issue":"1","key":"11057_CR162","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41416-022-02025-9","volume":"128","author":"G Curigliano","year":"2023","unstructured":"Curigliano, G., Shapiro, G. I., Kristeleit, R. S., Abdul Razak, A. R., Leong, S., Alsina, M., Giordano, A., Gelmon, K. A., Stringer-Reasor, E., Vaishampayan, U. N., Middleton, M., Olszanski, A. J., Rugo, H. S., Kern, K. A., Pathan, N., Perea, R., Pierce, K. J., Mutka, S. C., & Wainberg, Z. A. (2023). A phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. British Journal of Cancer, 128(1), 30\u201341. https:\/\/doi.org\/10.1038\/s41416-022-02025-9","journal-title":"British Journal of Cancer"},{"issue":"1","key":"11057_CR163","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01354-y","volume":"22","author":"AC Garrido-Castro","year":"2020","unstructured":"Garrido-Castro, A. C., Saura, C., Barroso-Sousa, R., Guo, H., Ciruelos, E., Bermejo, B., Gavil\u00e1, J., Serra, V., Prat, A., Par\u00e9, L., C\u00e9liz, P., Villagrasa, P., Li, Y., Savoie, J., Xu, Z., Arteaga, C. L., Krop, I. E., Solit, D. B., Mills, G. B., \u2026 Rodon, J. (2020). Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Research\u202f: BCR, 22(1), Article 120. https:\/\/doi.org\/10.1186\/s13058-020-01354-y","journal-title":"Breast Cancer Research : BCR"},{"issue":"1","key":"11057_CR164","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-02089-4","volume":"27","author":"E L\u00f3pez-Miranda","year":"2025","unstructured":"L\u00f3pez-Miranda, E., P\u00e9rez-Garc\u00eda, J. M., Gi\u00f3n, M., Ribelles, N., Cortez-Castedo, P., Alonso-Romero, J. L., Garc\u00eda, M. M., Gonz\u00e1lez-Santiago, S., Bermejo, B., Morales, S., Cara\u00f1ana, V., Garrig\u00f3s, L., Fern\u00e1ndez-Pinto, M., Garc\u00eda-Vicente, S., Garcia-Sanz, A., Mena-Molina, A., Boix, O., Alcal\u00e1-L\u00f3pez, D., Llombart-Cussac, A., & Cort\u00e9s, J. (2025). Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: The PATHFINDER phase IIa trial. Breast Cancer Research, 27(1), Article 141. https:\/\/doi.org\/10.1186\/s13058-025-02089-4","journal-title":"Breast Cancer Research"},{"issue":"4","key":"11057_CR165","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1158\/1078-0432.CCR-23-2084","volume":"30","author":"P Schmid","year":"2024","unstructured":"Schmid, P., Turner, N. C., Barrios, C. H., Isakoff, S. J., Kim, S. B., Sablin, M. P., Saji, S., Savas, P., Vidal, G. A., Oliveira, M., O\u2019Shaughnessy, J., Italiano, A., Espinosa, E., Boni, V., White, S., Rojas, B., Freitas-Junior, R., Chae, Y., Bondarenko, I., & Dent, R. (2024). First-line ipatasertib, atezolizumab, and taxane triplet for metastatic triple-negative breast cancer: Clinical and biomarker results. Clinical Cancer Research, 30(4), 767\u2013778. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2084","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"11057_CR166","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a000034","volume":"1","author":"A Oeckinghaus","year":"2009","unstructured":"Oeckinghaus, A., & Ghosh, S. (2009). The NF-kappaB family of transcription factors and its regulation. Cold Spring Harbor Perspectives in Biology, 1(4), Article a000034. https:\/\/doi.org\/10.1101\/cshperspect.a000034","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"1","key":"11057_CR167","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/cr.2009.137","volume":"20","author":"F Wan","year":"2010","unstructured":"Wan, F., & Lenardo, M. J. (2010). The nuclear signaling of NF-kappaB: Current knowledge, new insights, and future perspectives. Cell Research, 20(1), 24\u201333. https:\/\/doi.org\/10.1038\/cr.2009.137","journal-title":"Cell Research"},{"issue":"3","key":"11057_CR168","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jhep.2015.04.018","volume":"63","author":"JU Marquardt","year":"2015","unstructured":"Marquardt, J. U., Gomez-Quiroz, L., Arreguin Camacho, L. O., Pinna, F., Lee, Y. H., Kitade, M., Dom\u00ednguez, M. P., Castven, D., Breuhahn, K., Conner, E. A., Galle, P. R., Andersen, J. B., Factor, V. M., & Thorgeirsson, S. S. (2015). Curcumin effectively inhibits oncogenic NF-\u03baB signaling and restrains stemness features in liver cancer. Journal of Hepatology, 63(3), 661\u2013669. https:\/\/doi.org\/10.1016\/j.jhep.2015.04.018","journal-title":"Journal of Hepatology"},{"issue":"5","key":"11057_CR169","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/sj.cdd.4401843","volume":"13","author":"S Janssens","year":"2006","unstructured":"Janssens, S., & Tschopp, J. (2006). Signals from within: The DNA-damage-induced NF-kappaB response. Cell Death and Differentiation, 13(5), 773\u2013784. https:\/\/doi.org\/10.1038\/sj.cdd.4401843","journal-title":"Cell Death and Differentiation"},{"issue":"1","key":"11057_CR170","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01110-y","volume":"7","author":"F Peng","year":"2022","unstructured":"Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C., Fu, L., Chen, Y., & Han, B. (2022). Regulated cell death (RCD) in cancer: Key pathways and targeted therapies. Signal Transduction and Targeted Therapy, 7(1), Article 286. https:\/\/doi.org\/10.1038\/s41392-022-01110-y","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"10","key":"11057_CR171","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1158\/1078-0432.CCR-04-0703","volume":"10","author":"OP Veiby","year":"2004","unstructured":"Veiby, O. P., & Read, M. A. (2004). Chemoresistance: Impact of nuclear factor (NF)-kappaB inhibition by small interfering RNA. Commentary re J. Guo et al., Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the NF-kappaB p65 subunit. Clin Cancer Res 2004;10: 3333\u20133341. Clinical Cancer Research\u202f: An Official Journal of the American Association for Cancer Research, 10(10), 3262\u20133264. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0703","journal-title":"Clinical Cancer Research : An Official Journal of the American Association for Cancer Research"},{"issue":"1","key":"11057_CR172","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-03190-y","volume":"16","author":"I Debnath","year":"2025","unstructured":"Debnath, I., & Kundu, M. (2025). Therapeutic potential of natural compounds in targeting cancer stem cells: A promising approach for cancer treatment. Discover Oncology, 16(1), Article 1433. https:\/\/doi.org\/10.1007\/s12672-025-03190-y","journal-title":"Discover Oncology"},{"key":"11057_CR173","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.103920","volume":"182","author":"N Ebrahimi","year":"2023","unstructured":"Ebrahimi, N., Afshinpour, M., Fakhr, S. S., Kalkhoran, P. G., Shadman-Manesh, V., Adelian, S., Beiranvand, S., Rezaei-Tazangi, F., Khorram, R., Hamblin, M. R., & Aref, A. R. (2023). Cancer stem cells in colorectal cancer: Signaling pathways involved in stemness and therapy resistance. Critical Reviews in Oncology\/Hematology, 182, Article 103920. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103920","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"1","key":"11057_CR174","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01757-9","volume":"9","author":"Q Guo","year":"2024","unstructured":"Guo, Q., Jin, Y., Chen, X., Ye, X., Shen, X., Lin, M., Zeng, C., Zhou, T., & Zhang, J. (2024). NF-\u03baB in biology and targeted therapy: New insights and translational implications. Signal Transduction and Targeted Therapy, 9(1), Article 53. https:\/\/doi.org\/10.1038\/s41392-024-01757-9","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"3","key":"11057_CR175","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030703","volume":"15","author":"M Sirico","year":"2023","unstructured":"Sirico, M., D\u2019Angelo, A., Gianni, C., Casadei, C., Merloni, F., & De Giorgi, U. (2023). Current state and future challenges for PI3K inhibitors in cancer therapy. Cancers, 15(3), Article 703. https:\/\/doi.org\/10.3390\/cancers15030703","journal-title":"Cancers"},{"key":"11057_CR176","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1620807","volume":"16","author":"G Yu","year":"2025","unstructured":"Yu, G., & Gong, J. (2025). Targeting CSC-immune cell crosstalk to overcome chemoresistance and enhance immunotherapy efficacy. Frontiers in Immunology, 16, Article 1620807. https:\/\/doi.org\/10.3389\/fimmu.2025.1620807","journal-title":"Frontiers in Immunology"},{"issue":"9","key":"11057_CR177","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.21873\/anticanres.15924","volume":"42","author":"M Sukprasansap","year":"2022","unstructured":"Sukprasansap, M., & Chanvorachote, P. (2022). Evidence of potential plant-derived compounds with anticancer effects on lung cancer: Clinical and molecular pharmacology approaches. Anticancer Research, 42(9), 4247\u20134258. https:\/\/doi.org\/10.21873\/anticanres.15924","journal-title":"Anticancer Research"},{"issue":"2","key":"11057_CR178","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s13346-012-0079-x","volume":"3","author":"P Dandawate","year":"2013","unstructured":"Dandawate, P., Padhye, S., Ahmad, A., & Sarkar, F. H. (2013). Novel strategies targeting cancer stem cells through phytochemicals and their analogs. Drug Delivery and Translational Research, 3(2), 165\u2013182. https:\/\/doi.org\/10.1007\/s13346-012-0079-x","journal-title":"Drug Delivery and Translational Research"},{"issue":"9","key":"11057_CR179","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jnutbio.2010.11.001","volume":"22","author":"Y Li","year":"2011","unstructured":"Li, Y., Wicha, M. S., Schwartz, S. J., & Sun, D. (2011). Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. Journal of Nutritional Biochemistry, 22(9), 799\u2013806. https:\/\/doi.org\/10.1016\/j.jnutbio.2010.11.001","journal-title":"Journal of Nutritional Biochemistry"},{"issue":"22","key":"11057_CR180","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.2174\/0929867327666200228110738","volume":"28","author":"C Naujokat","year":"2021","unstructured":"Naujokat, C., & McKee, D. L. (2021). The \u201cBig five\u201d phytochemicals targeting cancer stem cells: Curcumin, EGCG, sulforaphane, resveratrol and genistein. Current Medicinal Chemistry, 28(22), 4321\u20134342. https:\/\/doi.org\/10.2174\/0929867327666200228110738","journal-title":"Current Medicinal Chemistry"},{"issue":"8","key":"11057_CR181","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3109\/10715762.2011.564168","volume":"45","author":"M Kelkel","year":"2011","unstructured":"Kelkel, M., Schumacher, M., Dicato, M., & Diederich, M. (2011). Antioxidant and anti-proliferative properties of lycopene. Free Radical Research, 45(8), 925\u2013940. https:\/\/doi.org\/10.3109\/10715762.2011.564168","journal-title":"Free Radical Research"},{"key":"11057_CR182","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2713511","volume":"2021","author":"UM Khan","year":"2021","unstructured":"Khan, U. M., Sevindik, M., Zarrabi, A., Nami, M., Ozdemir, B., Kaplan, D. N., Selamoglu, Z., Hasan, M., Kumar, M., Alshehri, M. M., & Sharifi-Rad, J. (2021). Lycopene: Food sources, biological activities, and human health benefits. Oxidative Medicine and Cellular Longevity, 2021, Article 2713511. https:\/\/doi.org\/10.1155\/2021\/2713511","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"11057_CR183","doi-asserted-by":"publisher","DOI":"10.4103\/jcar.JCar_15_20","volume":"20","author":"W Khan","year":"2021","unstructured":"Khan, W., Augustine, D., Rao, R. S., Patil, S., Awan, K. H., Sowmya, S. V., Haragannavar, V. C., & Prasad, K. (2021). Lipid metabolism in cancer: A systematic review. Journal of Carcinogenesis, 20, Article 4. https:\/\/doi.org\/10.4103\/jcar.JCar_15_20","journal-title":"Journal of Carcinogenesis"},{"issue":"2","key":"11057_CR184","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.3390\/cancers3022333","volume":"3","author":"P Palozza","year":"2011","unstructured":"Palozza, P., Simone, R. E., Catalano, A., & Mele, M. C. (2011). Tomato lycopene and lung cancer prevention: From experimental to human studies. Cancers, 3(2), 2333\u20132357. https:\/\/doi.org\/10.3390\/cancers3022333","journal-title":"Cancers"},{"issue":"7","key":"11057_CR185","doi-asserted-by":"publisher","first-page":"15727","DOI":"10.3390\/ijms160715727","volume":"16","author":"ES Scarpa","year":"2015","unstructured":"Scarpa, E. S., & Ninfali, P. (2015). Phytochemicals as innovative therapeutic tools against cancer stem cells. International Journal of Molecular Sciences, 16(7), 15727\u201315742. https:\/\/doi.org\/10.3390\/ijms160715727","journal-title":"International Journal of Molecular Sciences"},{"issue":"12","key":"11057_CR186","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1002\/ijc.25620","volume":"128","author":"AF Abdull Razis","year":"2011","unstructured":"Abdull Razis, A. F., Iori, R., & Ioannides, C. (2011). The natural chemopreventive phytochemical R-sulforaphane is a far more potent inducer of the carcinogen-detoxifying enzyme systems in rat liver and lung than the S-isomer. International Journal of Cancer, 128(12), 2775\u20132782. https:\/\/doi.org\/10.1002\/ijc.25620","journal-title":"International Journal of Cancer"},{"issue":"2","key":"11057_CR187","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s10637-014-0189-z","volume":"33","author":"JJ Alumkal","year":"2015","unstructured":"Alumkal, J. J., Slottke, R., Schwartzman, J., Cherala, G., Munar, M., Graff, J. N., Beer, T. M., Ryan, C. W., Koop, D. R., Gibbs, A., Gao, L., Flamiatos, J. F., Tucker, E., Kleinschmidt, R., & Mori, M. (2015). A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. Investigational New Drugs, 33(2), 480\u2013489. https:\/\/doi.org\/10.1007\/s10637-014-0189-z","journal-title":"Investigational New Drugs"},{"issue":"9","key":"11057_CR188","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/1078-0432.CCR-09-2937","volume":"16","author":"Y Li","year":"2010","unstructured":"Li, Y., Zhang, T., Korkaya, H., Liu, S., Lee, H. F., Newman, B., Yu, Y., Clouthier, S. G., Schwartz, S. J., Wicha, M. S., & Sun, D. (2010). Sulforaphane, a dietary component of broccoli\/broccoli sprouts, inhibits breast cancer stem cells. Clinical Cancer Research, 16(9), 2580\u20132590. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2937","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"11057_CR189","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2741\/e266","volume":"3","author":"RK Srivastava","year":"2011","unstructured":"Srivastava, R. K., Tang, S. N., Zhu, W., Meeker, D., & Shankar, S. (2011). Sulforaphane synergizes with quercetin to inhibit self-renewal capacity of pancreatic cancer stem cells. Frontiers in Bioscience (Elite Edition), 3(2), 515\u2013528. https:\/\/doi.org\/10.2741\/e266","journal-title":"Frontiers in Bioscience (Elite Edition)"},{"key":"11057_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118075","volume":"187","author":"M Ghasemi","year":"2025","unstructured":"Ghasemi, M., Nowroozzadeh, M. H., Ghorat, F., Iraji, A., & Hashempur, M. H. (2025). Piperine and its nanoformulations: A mechanistic review of their anti-cancer activities. Biomedicine & Pharmacotherapy, 187, Article 118075. https:\/\/doi.org\/10.1016\/j.biopha.2025.118075","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"11057_CR191","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.fct.2013.08.007","volume":"60","author":"DY Ouyang","year":"2013","unstructured":"Ouyang, D. Y., Zeng, L. H., Pan, H., Xu, L. H., Wang, Y., Liu, K. P., & He, X. H. (2013). Piperine inhibits the proliferation of human prostate cancer cells via induction of cell cycle arrest and autophagy. Food and Chemical Toxicology, 60, 424\u2013430. https:\/\/doi.org\/10.1016\/j.fct.2013.08.007","journal-title":"Food and Chemical Toxicology"},{"key":"11057_CR192","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10555-010-9238-z","volume":"29","author":"JM Pavese","year":"2010","unstructured":"Pavese, J. M., Farmer, R. L., & Bergan, R. C. (2010). Inhibition of cancer cell invasion and metastasis by genistein. Cancer and Metastasis Reviews, 29, 465\u2013482. https:\/\/doi.org\/10.1007\/s10555-010-9238-z","journal-title":"Cancer and Metastasis Reviews"},{"issue":"3","key":"11057_CR193","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26031114","volume":"26","author":"V Naponelli","year":"2025","unstructured":"Naponelli, V., Piscazzi, A., & Mangieri, D. (2025). Cellular and molecular mechanisms modulated by genistein in cancer. International Journal of Molecular Sciences, 26(3), Article 1114. https:\/\/doi.org\/10.3390\/ijms26031114","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"11057_CR194","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3945\/an.114.008052","volume":"6","author":"C Spagnuolo","year":"2015","unstructured":"Spagnuolo, C., Russo, G. L., Orhan, I. E., Habtemariam, S., Daglia, M., Sureda, A., Nabavi, S. F., Devi, K. P., Loizzo, M. R., Tundis, R., & Nabavi, S. M. (2015). Genistein and cancer: Current status, challenges, and future directions. Advances in Nutrition, 6(4), 408\u2013419. https:\/\/doi.org\/10.3945\/an.114.008052","journal-title":"Advances in Nutrition"},{"issue":"7","key":"11057_CR195","doi-asserted-by":"publisher","DOI":"10.1002\/fsn3.70608","volume":"13","author":"M Maaz","year":"2025","unstructured":"Maaz, M., Sultan, M. T., Khalid, M. U., Raza, H., Imran, M., Hussain, M., Al Abdulmonem, W., Alsagaby, S. A., Abdelgawad, M. A., Ghoneim, M. M., Khan, M. A., Yehuala, T. F., Selim, S., & Mostafa, E. M. (2025). A comprehensive review on the molecular mechanism of lycopene in cancer therapy. Food Science & Nutrition, 13(7), Article e70608. https:\/\/doi.org\/10.1002\/fsn3.70608","journal-title":"Food Science & Nutrition"},{"issue":"2","key":"11057_CR196","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/carcin\/bgs351","volume":"34","author":"R Preet","year":"2013","unstructured":"Preet, R., Mohapatra, P., Das, D., Satapathy, S. R., Choudhuri, T., Wyatt, M. D., & Kundu, C. N. (2013). Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC. Carcinogenesis, 34(2), 277\u2013286. https:\/\/doi.org\/10.1093\/carcin\/bgs351","journal-title":"Carcinogenesis"},{"key":"11057_CR197","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1089115","volume":"13","author":"LL Coutinho","year":"2023","unstructured":"Coutinho, L. L., Junior, T. C. T., & Rangel, M. C. (2023). Sulforaphane: An emergent anti-cancer stem cell agent. Frontiers in Oncology, 13, Article 1089115. https:\/\/doi.org\/10.3389\/fonc.2023.1089115","journal-title":"Frontiers in Oncology"},{"key":"11057_CR198","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5438179","volume":"2018","author":"X Su","year":"2018","unstructured":"Su, X., Jiang, X., Meng, L., Dong, X., Shen, Y., & Xin, Y. (2018). Anticancer activity of sulforaphane: The epigenetic mechanisms and the Nrf2 signaling pathway. Oxidative Medicine and Cellular Longevity, 2018, Article 5438179. https:\/\/doi.org\/10.1155\/2018\/5438179","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"8","key":"11057_CR199","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2217\/fon.13.108","volume":"9","author":"Y Li","year":"2013","unstructured":"Li, Y., & Zhang, T. (2013). Targeting cancer stem cells with sulforaphane, a dietary component from broccoli and broccoli sprouts. Future Oncology (London, England), 9(8), 1097\u20131103. https:\/\/doi.org\/10.2217\/fon.13.108","journal-title":"Future Oncology (London, England)"},{"key":"11057_CR200","doi-asserted-by":"publisher","first-page":"11681","DOI":"10.1038\/s41598-020-68574-2","volume":"10","author":"GC de Almeida","year":"2020","unstructured":"de Almeida, G. C., Oliveira, L. F. S., Predes, D., et al. (2020). Piperine suppresses the Wnt\/\u03b2-catenin pathway and has anti-cancer effects on colorectal cancer cells. Scientific Reports, 10, 11681. https:\/\/doi.org\/10.1038\/s41598-020-68574-2","journal-title":"Scientific Reports"},{"issue":"22","key":"11057_CR201","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15225488","volume":"15","author":"S Benayad","year":"2023","unstructured":"Benayad, S., Wahnou, H., El Kebbaj, R., Liagre, B., Sol, V., Oudghiri, M., Saad, E. M., Duval, R. E., & Limami, Y. (2023). The promise of piperine in cancer chemoprevention. Cancers, 15(22), Article 5488. https:\/\/doi.org\/10.3390\/cancers15225488","journal-title":"Cancers"},{"key":"11057_CR202","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2018.00010","volume":"6","author":"RA Rather","year":"2018","unstructured":"Rather, R. A., & Bhagat, M. (2018). Cancer chemoprevention and piperine: Molecular mechanisms and therapeutic opportunities. Frontiers in Cell and Developmental Biology, 6, Article 10. https:\/\/doi.org\/10.3389\/fcell.2018.00010","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"11057_CR203","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122943","volume":"354","author":"MK Manickasamy","year":"2024","unstructured":"Manickasamy, M. K., Kumar, A., Bharathwaj Chetty, B., Alqahtani, M. S., Abbas, M., Alqahtani, A., Unnikrishnan, J., Bishayee, A., Sethi, G., & Kunnumakkara, A. B. (2024). Synergistic enhancement: Exploring the potential of piperine in cancer therapeutics through chemosensitization and combination therapies. Life Sciences, 354, Article 122943. https:\/\/doi.org\/10.1016\/j.lfs.2024.122943","journal-title":"Life Sciences"},{"key":"11057_CR204","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01336","volume":"10","author":"HS Tuli","year":"2019","unstructured":"Tuli, H. S., Tuorkey, M. J., Thakral, F., Sak, K., Kumar, M., Sharma, A. K., Sharma, U., Jain, A., Aggarwal, V., & Bishayee, A. (2019). Molecular mechanisms of action of genistein in cancer: Recent advances. Frontiers in Pharmacology, 10, Article 1336. https:\/\/doi.org\/10.3389\/fphar.2019.01336","journal-title":"Frontiers in Pharmacology"},{"key":"11057_CR205","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1007\/s00044-009-9271-z","volume":"19","author":"X Zheng","year":"2010","unstructured":"Zheng, X., Yao, X., Liu, Y., et al. (2010). Synthesis and cytotoxic activity of genistein derivatives. Medicinal Chemistry Research, 19, 1296\u20131306. https:\/\/doi.org\/10.1007\/s00044-009-9271-z","journal-title":"Medicinal Chemistry Research"},{"issue":"21","key":"11057_CR206","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111669","volume":"22","author":"M Deldar Abad Paskeh","year":"2021","unstructured":"Deldar Abad Paskeh, M., Asadi, S., Zabolian, A., Saleki, H., Khoshbakht, M. A., Sabet, S., Naghdi, M. J., Hashemi, M., Hushmandi, K., Ashrafizadeh, M., Mirzaei, S., Zarrabi, A., & Sethi, G. (2021). Targeting cancer stem cells by dietary agents: An important therapeutic strategy against human malignancies. International Journal of Molecular Sciences, 22(21), Article 11669. https:\/\/doi.org\/10.3390\/ijms222111669","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"11057_CR207","doi-asserted-by":"publisher","first-page":"156","DOI":"10.2174\/1389202917666160803162309","volume":"18","author":"HF Torquato","year":"2017","unstructured":"Torquato, H. F., Goettert, M. I., Justo, G. Z., & Paredes-Gamero, E. J. (2017). Anti-cancer phytometabolites targeting cancer stem cells. Current Genomics, 18(2), 156\u2013174. https:\/\/doi.org\/10.2174\/1389202917666160803162309","journal-title":"Current Genomics"},{"issue":"12","key":"11057_CR208","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122864","volume":"14","author":"KS Prajapati","year":"2022","unstructured":"Prajapati, K. S., Gupta, S., & Kumar, S. (2022). Targeting breast cancer-derived stem cells by dietary phytochemicals: A strategy for cancer prevention and treatment. Cancers, 14(12), Article 2864. https:\/\/doi.org\/10.3390\/cancers14122864","journal-title":"Cancers"},{"issue":"6","key":"11057_CR209","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40262-025-01514-3","volume":"64","author":"C Coumau","year":"2025","unstructured":"Coumau, C., & Csajka, C. (2025). A systematic review and classification of the effects of P-glycoprotein inhibitors and inducers in humans, using digoxin, fexofenadine, and dabigatran as probe drugs. Clinical Pharmacokinetics, 64(6), 849\u2013863. https:\/\/doi.org\/10.1007\/s40262-025-01514-3","journal-title":"Clinical Pharmacokinetics"},{"issue":"2","key":"11057_CR210","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26020631","volume":"26","author":"A Filippi","year":"2025","unstructured":"Filippi, A., Deculescu-Ioni\u021b\u0103, T., Hudi\u021b\u0103, A., Baldasici, O., G\u0103l\u0103\u021beanu, B., & Mocanu, M. M. (2025). Molecular mechanisms of dietary compounds in cancer stem cells from solid tumors: Insights into colorectal, breast, and prostate cancer. International Journal of Molecular Sciences, 26(2), Article 631. https:\/\/doi.org\/10.3390\/ijms26020631","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"11057_CR211","doi-asserted-by":"publisher","DOI":"10.3390\/nu12061559","volume":"12","author":"D Kuran","year":"2020","unstructured":"Kuran, D., Pogorzelska, A., & Wiktorska, K. (2020). Breast cancer prevention-Is there a future for sulforaphane and its analogs? Nutrients, 12(6), Article 1559. https:\/\/doi.org\/10.3390\/nu12061559","journal-title":"Nutrients"},{"issue":"2","key":"11057_CR212","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12195-024-00798-y","volume":"17","author":"A Lamichhane","year":"2024","unstructured":"Lamichhane, A., & Tavana, H. (2024). Three-dimensional tumor models to study cancer stemness-mediated drug resistance. Cellular and Molecular Bioengineering, 17(2), 107\u2013119. https:\/\/doi.org\/10.1007\/s12195-024-00798-y","journal-title":"Cellular and Molecular Bioengineering"},{"issue":"5","key":"11057_CR213","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3390\/cells8050470","volume":"8","author":"J Kondo","year":"2019","unstructured":"Kondo, J., & Inoue, M. (2019). Application of cancer organoid model for drug screening and personalized therapy. Cells, 8(5), 470. https:\/\/doi.org\/10.3390\/cells8050470","journal-title":"Cells"},{"issue":"7","key":"11057_CR214","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","volume":"165","author":"H Clevers","year":"2016","unstructured":"Clevers, H. (2016). Modeling development and disease with organoids. Cell, 165(7), 1586\u20131597. https:\/\/doi.org\/10.1016\/j.cell.2016.05.082","journal-title":"Cell"},{"issue":"5","key":"11057_CR215","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s12015-024-10714-6","volume":"20","author":"Y Yang","year":"2024","unstructured":"Yang, Y., Kong, Y., Cui, J., Hou, Y., Gu, Z., & Ma, C. (2024). Advances and applications of cancer organoids in drug screening and personalized medicine. Stem Cell Reviews and Reports, 20(5), 1213\u20131226. https:\/\/doi.org\/10.1007\/s12015-024-10714-6","journal-title":"Stem Cell Reviews and Reports"},{"issue":"5","key":"11057_CR216","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41578-021-00279-y","volume":"6","author":"M Hofer","year":"2021","unstructured":"Hofer, M., & Lutolf, M. P. (2021). Engineering organoids. Nature Reviews Materials, 6(5), 402\u2013420. https:\/\/doi.org\/10.1038\/s41578-021-00279-y","journal-title":"Nature Reviews Materials"},{"issue":"10","key":"11057_CR217","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41580-020-0259-3","volume":"21","author":"J Kim","year":"2020","unstructured":"Kim, J., Koo, B., & Knoblich, J. A. (2020). Human organoids: Model systems for human biology and medicine. Nature Reviews Molecular Cell Biology, 21(10), 571\u2013584. https:\/\/doi.org\/10.1038\/s41580-020-0259-3","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"5","key":"11057_CR218","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/nbt.4127","volume":"36","author":"AA Mansour","year":"2018","unstructured":"Mansour, A. A., Gon\u00e7alves, J. T., Bloyd, C. W., Li, H., Fernandes, S., Quang, D., Johnston, S., Parylak, S. L., Jin, X., & Gage, F. H. (2018). An in vivo model of functional and vascularized human brain organoids. Nature Biotechnology, 36(5), 432\u2013441. https:\/\/doi.org\/10.1038\/nbt.4127","journal-title":"Nature Biotechnology"},{"issue":"12","key":"11057_CR219","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12122708","volume":"12","author":"Y Wang","year":"2024","unstructured":"Wang, Y., Chen, H., Zhang, Z., He, Y., Liu, J., Zhao, B., Wang, Q., Xu, J., Mao, S., Zhang, W., Yao, X., & Li, W. (2024). Precision treatment of metachronous multiple primary malignancies based on constructing patient tumor-derived organoids. Biomedicines, 12(12), Article 2708. https:\/\/doi.org\/10.3390\/biomedicines12122708","journal-title":"Biomedicines"},{"issue":"4","key":"11057_CR220","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1002\/jcp.26052","volume":"233","author":"ET Verjans","year":"2018","unstructured":"Verjans, E. T., Doijen, J., Luyten, W., Landuyt, B., & Schoofs, L. (2018). Three-dimensional cell culture models for anticancer drug screening: Worth the effort? Journal of Cellular Physiology, 233(4), 2993\u20133003. https:\/\/doi.org\/10.1002\/jcp.26052","journal-title":"Journal of Cellular Physiology"},{"issue":"7","key":"11057_CR221","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s12276-024-01272-5","volume":"56","author":"L Thorel","year":"2024","unstructured":"Thorel, L., Perr\u00e9ard, M., Florent, R., Divoux, J., Coffy, S., Vincent, A., Gaggioli, C., Guasch, G., Gidrol, X., Weiswald, L., & Poulain, L. (2024). Patient-derived tumor organoids: A new avenue for preclinical research and precision medicine in oncology. Experimental & Molecular Medicine, 56(7), 1531\u20131551. https:\/\/doi.org\/10.1038\/s12276-024-01272-5","journal-title":"Experimental & Molecular Medicine"},{"key":"11057_CR222","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177368","volume":"993","author":"Y Wang","year":"2025","unstructured":"Wang, Y., Sun, X., Lu, B., Zhang, D., Yin, Y., Liu, S., Chen, L., & Zhang, Z. (2025). Current applications, future perspectives and challenges of organoid technology in oral cancer research. European Journal of Pharmacology, 993, Article 177368. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177368","journal-title":"European Journal of Pharmacology"},{"issue":"3","key":"11057_CR223","doi-asserted-by":"publisher","DOI":"10.1088\/1758-5090\/acd95f","volume":"15","author":"Y Choi","year":"2023","unstructured":"Choi, Y., Lee, H., Ann, M., Song, M., Rheey, J., & Jang, J. (2023). 3D bioprinted vascularized lung cancer organoid models with underlying disease capable of more precise drug evaluation. Biofabrication, 15(3), Article 034104. https:\/\/doi.org\/10.1088\/1758-5090\/acd95f","journal-title":"Biofabrication"},{"issue":"1","key":"11057_CR224","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.102","volume":"3","author":"K Sharma","year":"2024","unstructured":"Sharma, K., Dey, S., Karmakar, R., & Rengan, A. K. (2024). A comprehensive review of 3D cancer models for drug screening and translational research. Cancer Innovation, 3(1), Article e102. https:\/\/doi.org\/10.1002\/cai2.102","journal-title":"Cancer Innovation"},{"key":"11057_CR225","doi-asserted-by":"publisher","DOI":"10.1093\/stmcls\/sxae070","author":"J Zuo","year":"2025","unstructured":"Zuo, J., Fang, Y., Wang, R., & Liang, S. (2025). High-throughput solutions in tumor organoids: From culture to drug screening. Stem Cells. https:\/\/doi.org\/10.1093\/stmcls\/sxae070","journal-title":"Stem Cells"},{"issue":"4","key":"11057_CR226","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/adt.2014.573","volume":"12","author":"R Edmondson","year":"2014","unstructured":"Edmondson, R., Broglie, J. J., Adcock, A. F., & Yang, L. (2014). Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay and Drug Development Technologies, 12(4), 207\u2013218. https:\/\/doi.org\/10.1089\/adt.2014.573","journal-title":"Assay and Drug Development Technologies"},{"issue":"1","key":"11057_CR227","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jcp.24683","volume":"230","author":"M Ravi","year":"2015","unstructured":"Ravi, M., Paramesh, V., Kaviya, S. R., Anuradha, E., & Solomon, F. D. (2015). 3D cell culture systems: Advantages and applications. Journal of Cellular Physiology, 230(1), 16\u201326. https:\/\/doi.org\/10.1002\/jcp.24683","journal-title":"Journal of Cellular Physiology"},{"issue":"10","key":"11057_CR228","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nrm2236","volume":"8","author":"F Pampaloni","year":"2007","unstructured":"Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. (2007). The third dimension bridges the gap between cell culture and live tissue. Nature Reviews. Molecular Cell Biology, 8(10), 839\u2013845. https:\/\/doi.org\/10.1038\/nrm2236","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"5","key":"11057_CR229","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1177\/1087057117696795","volume":"22","author":"Y Fang","year":"2017","unstructured":"Fang, Y., & Eglen, R. M. (2017). Three-dimensional cell cultures in drug discovery and development. SLAS Discovery\u202f: Advancing Life Sciences R & D, 22(5), 456\u2013472. https:\/\/doi.org\/10.1177\/1087057117696795","journal-title":"SLAS Discovery : Advancing Life Sciences R & D"},{"issue":"4","key":"11057_CR230","doi-asserted-by":"publisher","first-page":"910","DOI":"10.5114\/aoms.2016.63743","volume":"14","author":"M Kapa\u0142czy\u0144ska","year":"2018","unstructured":"Kapa\u0142czy\u0144ska, M., Kolenda, T., Przyby\u0142a, W., Zaj\u0105czkowska, M., Teresiak, A., Filas, V., Ibbs, M., Bli\u017aniak, R., \u0141uczewski, \u0141, & Lamperska, K. (2018). 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Archives of Medical Science, 14(4), 910\u2013919. https:\/\/doi.org\/10.5114\/aoms.2016.63743","journal-title":"Archives of Medical Science"},{"key":"11057_CR231","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7007-10-29","volume":"10","author":"M Vinci","year":"2012","unstructured":"Vinci, M., Gowan, S., Boxall, F., Patterson, L., Zimmermann, M., Court, W., Lomas, C., Mendiola, M., Hardisson, D., & Eccles, S. A. (2012). Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biology, 10, Article 29. https:\/\/doi.org\/10.1186\/1741-7007-10-29","journal-title":"BMC Biology"},{"issue":"3","key":"11057_CR232","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.3390\/ijms16035517","volume":"16","author":"D Antoni","year":"2015","unstructured":"Antoni, D., Burckel, H., Josset, E., & Noel, G. (2015). Three-dimensional cell culture: A breakthrough in vivo. International Journal of Molecular Sciences, 16(3), 5517\u20135527. https:\/\/doi.org\/10.3390\/ijms16035517","journal-title":"International Journal of Molecular Sciences"},{"issue":"5","key":"11057_CR233","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41578-018-0006-y","volume":"3","author":"L Moroni","year":"2018","unstructured":"Moroni, L., Burdick, J. A., Highley, C., Lee, S. J., Morimoto, Y., Takeuchi, S., & Yoo, J. J. (2018). Biofabrication strategies for 3D in vitro models and regenerative medicine. Nature Reviews Materials, 3(5), 21\u201337. https:\/\/doi.org\/10.1038\/s41578-018-0006-y","journal-title":"Nature Reviews Materials"},{"issue":"12","key":"11057_CR234","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1039\/c2lc40089h","volume":"12","author":"D Huh","year":"2012","unstructured":"Huh, D., Torisawa, Y. S., Hamilton, G. A., Kim, H. J., & Ingber, D. E. (2012). Microengineered physiological biomimicry: Organs-on-chips. Lab on a Chip, 12(12), 2156\u20132164. https:\/\/doi.org\/10.1039\/c2lc40089h","journal-title":"Lab on a Chip"},{"issue":"9","key":"11057_CR235","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.chembiol.2017.06.012","volume":"24","author":"F Weeber","year":"2017","unstructured":"Weeber, F., Ooft, S. N., Dijkstra, K. K., & Voest, E. E. (2017). Tumor organoids as a pre-clinical cancer model for drug discovery. Cell Chemical Biology, 24(9), 1092\u20131100. https:\/\/doi.org\/10.1016\/j.chembiol.2017.06.012","journal-title":"Cell Chemical Biology"},{"issue":"19","key":"11057_CR236","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194768","volume":"15","author":"J Kim","year":"2023","unstructured":"Kim, J., Kim, M. Y., & Hong, S. (2023). Synergistic effects of metformin and trastuzumab on HER2 positive gastroesophageal adenocarcinoma cells in vitro and in vivo. Cancers, 15(19), Article 4768. https:\/\/doi.org\/10.3390\/cancers15194768","journal-title":"Cancers"},{"issue":"4","key":"11057_CR237","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41571-019-0293-2","volume":"17","author":"JA Clara","year":"2020","unstructured":"Clara, J. A., Monge, C., Yang, Y., & Takebe, N. (2020). Targeting signalling pathways and the immune microenvironment of cancer stem cells - A clinical update. Nature Reviews. Clinical Oncology, 17(4), 204\u2013232. https:\/\/doi.org\/10.1038\/s41571-019-0293-2","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"6","key":"11057_CR238","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1007\/s13277-012-0478-0","volume":"33","author":"SD Vangipuram","year":"2012","unstructured":"Vangipuram, S. D., Buck, S. A., & Lyman, W. D. (2012). Wnt pathway activity confers chemoresistance to cancer stem-like cells in a neuroblastoma cell line. Tumour Biology\u202f: The Journal of the International Society for Oncodevelopmental Biology and Medicine, 33(6), 2173\u20132183. https:\/\/doi.org\/10.1007\/s13277-012-0478-0","journal-title":"Tumour Biology : The Journal of the International Society for Oncodevelopmental Biology and Medicine"},{"issue":"1","key":"11057_CR239","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1360-3","volume":"38","author":"SS Islam","year":"2019","unstructured":"Islam, S. S., & Aboussekhra, A. (2019). Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway. Journal of Experimental & Clinical Cancer Research, 38(1), Article 382. https:\/\/doi.org\/10.1186\/s13046-019-1360-3","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"18","key":"11057_CR240","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1038\/onc.2012.252","volume":"32","author":"C Gong","year":"2013","unstructured":"Gong, C., Bauvy, C., Tonelli, G., Yue, W., Delom\u00e9nie, C., Nicolas, V., Zhu, Y., Domergue, V., Marin-Esteban, V., Tharinger, H., Delbos, L., Gary-Gouy, H., Morel, A. P., Ghavami, S., Song, E., Codogno, P., & Mehrpour, M. (2013). Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like\/progenitor cells. Oncogene, 32(18), 2261-2272e.11. https:\/\/doi.org\/10.1038\/onc.2012.252","journal-title":"Oncogene"},{"issue":"7","key":"11057_CR241","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.327","volume":"8","author":"A Pagotto","year":"2017","unstructured":"Pagotto, A., Pilotto, G., Mazzoldi, E. L., Nicoletto, M. O., Frezzini, S., Past\u00f2, A., & Amadori, A. (2017). Autophagy inhibition reduces chemoresistance and tumorigenic potential of human ovarian cancer stem cells. Cell Death & Disease, 8(7), Article e2943. https:\/\/doi.org\/10.1038\/cddis.2017.327","journal-title":"Cell Death & Disease"},{"issue":"2","key":"11057_CR242","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3892\/ijo.2017.4047","volume":"51","author":"X Ran","year":"2017","unstructured":"Ran, X., Zhou, P., & Zhang, K. (2017). Autophagy plays an important role in stemness mediation and the novel dual function of EIG121 in both autophagy and stemness regulation of endometrial carcinoma JEC cells. International Journal of Oncology, 51(2), 644\u2013656. https:\/\/doi.org\/10.3892\/ijo.2017.4047","journal-title":"International Journal of Oncology"},{"issue":"5","key":"11057_CR243","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16050957","volume":"16","author":"L Bhagtaney","year":"2024","unstructured":"Bhagtaney, L., Dharmarajan, A., & Warrier, S. (2024). MiRNA on the battlefield of cancer: Significance in cancer stem cells, WNT pathway, and treatment. Cancers, 16(5), Article 957. https:\/\/doi.org\/10.3390\/cancers16050957","journal-title":"Cancers"},{"issue":"1","key":"11057_CR244","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12010193","volume":"12","author":"N Alsadi","year":"2024","unstructured":"Alsadi, N., Yahfoufi, N., Nessim, C., & Matar, C. (2024). Role of a polyphenol-enriched blueberry preparation on inhibition of melanoma cancer stem cells and modulation of microRNAs. Biomedicines, 12(1), Article 193. https:\/\/doi.org\/10.3390\/biomedicines12010193","journal-title":"Biomedicines"},{"issue":"2","key":"11057_CR245","doi-asserted-by":"publisher","first-page":"298","DOI":"10.20517\/cdr.2020.92","volume":"4","author":"S Shaikh","year":"2021","unstructured":"Shaikh, S., Shaikh, J., Naba, Y. S., Doke, K., Ahmed, K., & Yusufi, M. (2021). Curcumin: Reclaiming the lost ground against cancer resistance. Cancer Drug Resistance (Alhambra, Calif.), 4(2), 298\u2013320. https:\/\/doi.org\/10.20517\/cdr.2020.92","journal-title":"Cancer Drug Resistance (Alhambra, Calif.)"},{"issue":"7","key":"11057_CR246","first-page":"1588","volume":"7","author":"WF Taylor","year":"2017","unstructured":"Taylor, W. F., & Jabbarzadeh, E. (2017). The use of natural products to target cancer stem cells. American Journal of Cancer Research, 7(7), 1588\u20131605.","journal-title":"American Journal of Cancer Research"},{"issue":"1","key":"11057_CR247","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016530","volume":"6","author":"S Shankar","year":"2011","unstructured":"Shankar, S., Nall, D., Tang, S. N., Meeker, D., Passarini, J., Sharma, J., & Srivastava, R. K. (2011). Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS ONE, 6(1), Article e16530. https:\/\/doi.org\/10.1371\/journal.pone.0016530","journal-title":"PLoS ONE"},{"key":"11057_CR248","doi-asserted-by":"publisher","DOI":"10.1186\/1750-2187-5-14","volume":"5","author":"SN Tang","year":"2010","unstructured":"Tang, S. N., Singh, C., Nall, D., Meeker, D., Shankar, S., & Srivastava, R. K. (2010). The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. Journal of Molecular Signaling, 5, Article 14. https:\/\/doi.org\/10.1186\/1750-2187-5-14","journal-title":"Journal of Molecular Signaling"},{"key":"11057_CR249","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114526","volume":"161","author":"J Li","year":"2023","unstructured":"Li, J., Yang, H., Zhang, L., Zhang, S., & Dai, Y. (2023). Metabolic reprogramming and interventions in endometrial carcinoma. Biomedicine & Pharmacotherapy, 161, Article 114526. https:\/\/doi.org\/10.1016\/j.biopha.2023.114526","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"2","key":"11057_CR250","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2022.13407","volume":"24","author":"X Li","year":"2022","unstructured":"Li, X., Liu, M., Liu, H., & Chen, J. (2022). Tumor metabolic reprogramming in lung cancer progression. Oncology Letters, 24(2), Article 287. https:\/\/doi.org\/10.3892\/ol.2022.13407","journal-title":"Oncology Letters"},{"issue":"2","key":"11057_CR251","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.218","volume":"4","author":"S Nong","year":"2023","unstructured":"Nong, S., Han, X., Xiang, Y., Qian, Y., Wei, Y., Zhang, T., Tian, K., Shen, K., Yang, J., & Ma, X. (2023). Metabolic reprogramming in cancer: Mechanisms and therapeutics. MedComm, 4(2), Article e218. https:\/\/doi.org\/10.1002\/mco2.218","journal-title":"MedComm"},{"issue":"1482","key":"11057_CR252","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1098\/rstb.2007.2026","volume":"362","author":"GB Zhou","year":"2007","unstructured":"Zhou, G. B., Zhang, J., Wang, Z. Y., Chen, S. J., & Chen, Z. (2007). Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: A paradigm of synergistic molecular targeting therapy. Philosophical Transactions of the Royal Society B: Biological Sciences, 362(1482), 959\u2013971. https:\/\/doi.org\/10.1098\/rstb.2007.2026","journal-title":"Philosophical Transactions of the Royal Society B: Biological Sciences"},{"issue":"2","key":"11057_CR253","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3390\/cancers12020516","volume":"12","author":"S Nayak","year":"2020","unstructured":"Nayak, S., Mahenthiran, A., Yang, Y., McClendon, M., Mania-Farnell, B., James, C. D., Kessler, J. A., Tomita, T., Cheng, S. Y., Stupp, S. I., & Xi, G. (2020). Bone morphogenetic protein 4 targeting glioma stem-like cells for malignant glioma treatment: Latest advances and implications for clinical application. Cancers, 12(2), 516. https:\/\/doi.org\/10.3390\/cancers12020516","journal-title":"Cancers"},{"issue":"22","key":"11057_CR254","doi-asserted-by":"publisher","first-page":"5201","DOI":"10.1182\/blood-2012-01-401687","volume":"119","author":"T Bhatla","year":"2012","unstructured":"Bhatla, T., Wang, J., Morrison, D. J., Raetz, E. A., Burke, M. J., Brown, P., & Carroll, W. L. (2012). Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood, 119(22), 5201\u20135210. https:\/\/doi.org\/10.1182\/blood-2012-01-401687","journal-title":"Blood"},{"issue":"9","key":"11057_CR255","doi-asserted-by":"publisher","DOI":"10.3390\/jfb14090466","volume":"14","author":"A Crintea","year":"2023","unstructured":"Crintea, A., Constantin, A. M., Motofelea, A. C., Crivii, C. B., Velescu, M. A., Co\u0219eriu, R. L., Ily\u00e9s, T., Cr\u0103ciun, A. M., & Silaghi, C. N. (2023). Targeted EGFR nanotherapy in non-small cell lung cancer. Journal of Functional Biomaterials, 14(9), Article 466. https:\/\/doi.org\/10.3390\/jfb14090466","journal-title":"Journal of Functional Biomaterials"},{"issue":"9","key":"11057_CR256","doi-asserted-by":"publisher","DOI":"10.3390\/biom12091239","volume":"12","author":"D Nie","year":"2022","unstructured":"Nie, D., Guo, T., Yue, M., Li, W., Zong, X., Zhu, Y., Huang, J., & Lin, M. (2022). Research progress on nanoparticles-based CRISPR\/Cas9 system for targeted therapy of tumors. Biomolecules, 12(9), Article 1239. https:\/\/doi.org\/10.3390\/biom12091239","journal-title":"Biomolecules"},{"key":"11057_CR257","doi-asserted-by":"publisher","DOI":"10.37349\/eds.2025.1008106","volume":"3","author":"JK Opara","year":"2025","unstructured":"Opara, J. K., Sanchez, S., Thomas, S. M., & Anant, S. (2025). Natural products targeting cancer stem cells: A promising therapeutic approach. Exploration of Drug Science, 3, Article 1008106. https:\/\/doi.org\/10.37349\/eds.2025.1008106","journal-title":"Exploration of Drug Science"},{"issue":"10","key":"11057_CR258","doi-asserted-by":"publisher","DOI":"10.3390\/cells14100717","volume":"14","author":"M Milella","year":"2025","unstructured":"Milella, M., Rutigliano, M., Pandolfo, S. D., Aveta, A., Crocetto, F., Ferro, M., d\u2019Amati, A., Ditonno, P., Lucarelli, G., & Lasorsa, F. (2025). The metabolic landscape of cancer stem cells: Insights and implications for therapy. Cells, 14(10), Article 717. https:\/\/doi.org\/10.3390\/cells14100717","journal-title":"Cells"},{"key":"11057_CR259","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ejphar.2014.06.025","volume":"740","author":"P Jabbarzadeh Kaboli","year":"2014","unstructured":"Jabbarzadeh Kaboli, P., Rahmat, A., Ismail, P., & Ling, K. H. (2014). Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer. European Journal of Pharmacology, 740, 584\u2013595. https:\/\/doi.org\/10.1016\/j.ejphar.2014.06.025","journal-title":"European Journal of Pharmacology"},{"key":"11057_CR260","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/8722803","volume":"2023","author":"SM Alnasser","year":"2023","unstructured":"Alnasser, S. M. (2023). Advances and challenges in cancer stem cells for onco-therapeutics. Stem Cells International, 2023, Article 8722803. https:\/\/doi.org\/10.1155\/2023\/8722803","journal-title":"Stem Cells International"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-026-11057-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T11:17:22Z","timestamp":1772623042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12015-026-11057-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":260,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["11057"],"URL":"https:\/\/doi.org\/10.1007\/s12015-026-11057-0","relation":{},"ISSN":["2629-3269","2629-3277"],"issn-type":[{"value":"2629-3269","type":"print"},{"value":"2629-3277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}